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Toxin-antitoxin (TA) systems are essential for bacterial persistence under stressful conditions. 
In particular, M. tuberculosis express VapBC TA genes that encode the stable VapC toxin and 
the labile VapB antitoxin. Under normal conditions, these proteins interact to form a non-toxic 
TA complex, but the toxin is activated by release from the antitoxin in response to unfavorable 
conditions. Here, we present the crystal structure of the M. tuberculosis VapBC26 complex and 
show that the VapC26 toxin contains a pilus retraction protein (PilT) N-terminal (PIN) domain 
that is essential for ribonuclease activity and that, the VapB26 antitoxin folds into a ribbon-
helix-helix DNA-binding motif at the N-terminus. The active site of VapC26 is sterically 
blocked by the flexible C-terminal region of VapB26. The C-terminal region of free VapB26 
adopts an unfolded conformation but forms a helix upon binding to VapC26. The results of 
RNase activity assays show that Mg2+ and Mn2+ are essential for the ribonuclease activity of 
VapC26. As shown in the nuclear magnetic resonance (NMR) spectra, several residues of 
VapB26 participate in the specific binding to the promoter region of the VapBC26 operon. In 
addition, toxin-mimicking peptides were designed that inhibit TA complex formation and 
iii
thereby increase toxin activity, providing a novel approach to the development of new 
antibiotics 
Pneumoniae, an inflammatory human lung disease, is caused by Streptococcus pneumoniae, 
which has received growing attention for its resistance to existing antibiotics. S. pneumoniae 
TIGR4 contains six toxin-antitoxin (TA) pairs of type II TA systems that are essential for 
bacterial persistence against stressful conditions such as nutrient deprivation, antibiotic 
treatment, and immune system attacks. In particular, S.pneumoniae express HicBA TA gene that 
encode the stable HicA toxin and labile HicB antitoxin. These proteins interact to form a non-
toxic TA complex under normal conditions, but the toxin is activated by release from the 
antitoxin in response to unfavorable growth conditions. Here, we present the first crystal 
structure showing entire conformation of the HicBA complex from S.pneumoniae, revealing that 
the HicA toxin contains a double-stranded RNA binding domain (dsRBD) that is essential for 
RNA recognition, whereas the HicB antitoxin folds into a ribbon-helix-helix (RHH) DNA-
binding motif at the C-terminus. The active site of HicA is sterically blocked by the N-terminal 
region of HicB. According to the RNase activity assays, His36 is essential for the ribonuclease 
activity of HicA. As shown in the NMR spectra, several residues of HicB participate in the 
specific binding to the promotor DNA of the HicBA operon. In addition, toxin-mimicking 
peptide was designed to inhibit TA complex formation and thereby increase toxin activity, 
providing a novel approach for the development of new antibiotics. 
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General Introduction 
There is increasing evidence that TA systems are strongly correlated with bacterial 
physiology and that they interact with cellular processes involved in gene 
regulation, growth arrest, survival, and apoptosis (1-5). TA loci were first 
discovered in 1983 on the mini-F plasmid of Escherichia coli, a plasmid addiction 
module that is responsible for the maintenance of extrachromosomal genetic 
elements (6). TA systems located on plasmids are transferred to daughter cells and 
are involved in plasmid stabilization and cell viability (7,8). If the daughter cell 
primarily inherits plasmids that lack TA genes, it cannot produce antitoxins but still 
produces residual TA complexes (9). In this situation, a toxin becomes highly 
activated upon dissociation from the corresponding antitoxin, which is then 
degraded by cellular proteases, resulting in cell death (10). In contrast, 
chromosomal TA systems are commonly related to growth arrest, biofilm formation 
(11) and multidrug tolerance (12,13), all of which facilitate the development of 
persister or dormant cells (14). These toxins damage host cells by inducing RNA 
degradation or by binding to topoisomerase to or ribosomes (15-17). In contrast, an 
antitoxin is an important cellular components for cell maintenance and viability 
because it neutralizes the detrimental activity of its cognate toxin (18).  
 
TA systems are classified into five groups: type I-V TA systems. In the type I TA 
system, antitoxins are antisense RNAs that bind to toxins, which are mRNAs. 
Antitoxins inhibit the translation of toxin and make it be degraded. In the type II 
TA system, both toxins and antitoxins are proteins that interact with each other to 
form a non-toxic protein complex. In the type III TA system, antitoxins act as 
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RNAs that bind directly to toxin protein. They make non-toxic RNA-protein 
complex. In the type IV TA systems, toxins and antitoxins do not bind directly but 
they compete to take same cellular target. In the type V TA system, antitoxins are  
proteins that degrade toxins to be unexpressed (19-23). VapBC and HicBA belongs 
to type II TA system. In the type II TA system, the toxin is thermodynamically 
stable, whereas the antitoxin is unstable and cleaved by cellular proteases because 
of its locally flexible conformation that is susceptible to proteolysis. According to 
the proteolysis of antitoxin, free toxin is released from TA complex and binds to 





Chapter 1. Functional details of the Mycobacterium 
tuberculosis VapBC26 toxin-antitoxin system 
1. 1 Introduction   
Mycobacterium tuberculosis has co-existed with humans for at least 15,000 years 
(26). This bacterium is aerobic, non-spore forming, non-motile, and may be either 
gram-negative or gram-positive (27-29). M. tuberculosis causes tuberculosis, 
which claims approximately 2 million lives per year worldwide (30). Notably, 
multi-drug resistant tuberculosis (MDR-TB) has emerged as a global concern over 
the past few decades, and approximately 350,000 new MDR-TB cases occur 
annually worldwide (31). Extensively drug-resistant tuberculosis strains (MDR-TB 
and XDR-TB, which are resistant to fluoroquinolones and second-line injectables) 
have been reported in 72% of countries studied (32). Therefore, the development of 
new antibiotics that can be used to eradicate M. tuberculosis by exploiting new 
therapeutic strategies is urgently needed. 
 
Pathogenic bacteria, such as M. tuberculosis utilize many toxin-antitoxin (TA) 
systems to survive, but non-pathogenic bacteria, such as Mycobacterium smegmatis, 
are reported to use only five TA systems (33). M. tuberculosis has a very low 
growth rate and a long incubation period, whereas M. smegmatis is a free-living 
bacterium that grows rapidly. Thus, the growth, survival and pathogenicity of these 
bacterial species are closely related to the number of TA loci. Furthermore, TA loci 
do not exist in humans but specifically exist in bacteria. Therefore, TA systems 
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represent potential antibiotic targets (34). 
 
Eighty-eight type II TA operons have been identified in M. tuberculosis; of these, 
45 belong to the VapBC family (35,36). The VapBC TA family is one of the most 
widely distributed type II TA families throughout bacterial species. However, 
crystal structures have been determined for only six VapBC TA complexes to date: 
four from M. tuberculosis, Protein Data Bank (PDB) code 3H87 (VapBC3), PDB 
code 3DBO (VapBC5), PDB code 4CHG (VapBC15), and PDB code 4XGQ 
(VapBC30) (37-40); one from Rickettsia felis (PDB code 3ZVK); and one from 
Shigella flexneri (PDB code 3TND) (41,42). However, the physiological roles of 
these complexes have not yet been clearly elucidated (38).  
 
VapC toxins commonly contain a PilT N-terminal (PIN) domain that exhibits 
ribonuclease activity toward cellular mRNAs (43,44). The active sites of VapC 
toxins consist of three conserved acidic residues that coordinate divalent metal ions 
such as Mg2+ (45-48), suggesting an acid-base catalysis mechanism for the 
nucleolytic activity of VapC toxins. VapC26 targets the 23S rRNA in the sarcin-
ricin-loop, which is crucial for translation and ribosomal activity (49,50). Only two 
sarcin-ricin-loop endoribonucleases, VapC20 and VapC26, have been reported in M. 
tuberculosis, (47,49). VapB antitoxins consist of the following two functional 
motifs: an N-terminal region that binds to the promoter DNA of the TA operon and 
a C-terminal region that binds to the toxin and thereby abolishes its toxicity (51). 
The antitoxin alone or in complex with the cognate toxin acts as a repressor that 
auto-regulates the transcription of  the TA operon in a negative feedback loop (52).  
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Here, we present the crystal structure of the VapBC26 complex from M. 
tuberculosis at a resolution of 2.653 Å. The structure reveals the important residues 
involved in binding to the promoter DNA and in the formation of the VapBC26 
complex. The VapC26 toxin forms an overall α/β/α structure with four parallel β 
strands, and VapB26 adopts a ribbon-helix-helix (RHH) DNA-binding motif. The 
core residues in VapB26 that bind to DNA and the structural changes in VapB26 
resulting that result from toxin binding were clarified by nuclear magnetic 
resonance (NMR). The catalytic site of VapC26 is composed of three conserved 
acidic residues; two of these, Asp4 and Asp97, interact directly with Mg2+. The 
ribonuclease activity of VapC26 was confirmed in this study. Several peptides were 
designed as antibiotic candidates to mimic the binding interface of the VapBC26 
complex and thereby suppressing the TA interaction. This approach may contribute 
to the development of novel, potent antibiotics that can be used to effectively treat 




1.2 Experimental procedure 
1.2.1 Cloning and transformation 
The VapC26 (Rv0582) and VapB26 (Rv0581) genes were amplified by the 
polymerase chain reaction (PCR). The primers used in PCR were as follows: for 
VapB26, forward, 5’-G GAA TTC CAT ATG GAC AAG ACG ACG GTC-3’; 
reverse, 5’-TTA CCG CTC GAG CCG CTC ACC GAA GCC AGC CAG-3’; for 
VapC26, forward, 5’-G GAA TTC CAT ATG ATC ATC GAC ACG AGT GCG; and 
reverse, 5’-CCG CTC GAG TTA CGG AAT GAC GGT GAA CGC CCC. DNA 
was purchased from Bioneer Innovation (Republic of Korea). The restriction 
enzymes used for cloning were Nde1 and Xho1; the enzyme cutting sites are 
underlined above. Restriction enzymes were purchased from New England Biolabs 
(http://www.neb.com/). The PCR products of VapB26 and VapC26 were double-cut 
by Nde1 and Xho1 and ligated to vectors that had been cut by the same enzymes. 
For structure determination and biological assays, VapB26 and VapC26 were 
ligated to pET21a without a tag and to pET28b, respectively. The pET28b N-
terminal tag (MGSSHHHHHHSSGLVPRGSH) was added to VapC26 as an 
additional residual tag. For NMR experiments, VapB26 was ligated to pET28b 
resulting in an N-terminal additional residual tag 
(MGSSHHHHHHSSGLVPRGSH). Each plasmid was then transformed into E. coli 
DH5α competent cells.  
 
1.2.2 Protein expression and purification 
For crystallization, the cloned plasmids of VapB26 and VapC26 were co-
transformed into E. coli Rosetta2 (DE3) pLyss competent cells. The transformed 
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cells were grown at 37˚C in Luria broth (LB) until the OD600 of the culture reached 
0.8. Protein overexpression was induced by the addition of 0.5 mM isopropyl 1-
thio-β-D-galactopyranoside (IPTG), and the culture was further incubated at 37˚C 
for 4 h. The cultured cells were harvested by centrifugation at 11,355 x g at 4 ˚C 
and stored at -80˚C. The harvested cells were then suspended in buffer A (20 mM 
Tris-HCl, pH 7.9, and 500 mM NaCl) and lysed by ultrasonication. After 
centrifugation for 1 h at 28,306 x g, the supernatant containing soluble proteins was 
loaded on a Ni2+ affinity column (Bio-Rad) equilibrated with buffer A and washed 
with buffer A containing 100 mM imidazole. The protein bound to the Ni2+ column 
was eluted using an imidazole gradient (150−800 mM), and the TA complex 
present in the elution fractions was identified by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS−PAGE). Finally, the buffer in fractions 
containing the TA complex was exchanged for buffer consisting of 50 mM Tris-
HCl, pH 7.9, 500 mM NaCl and 250 mM imidazole using an Amicon Ultra 
centrifugal filter unit (Millipore), and the sample was concentrated to 5 mg/ml. The 
purity of the TA complex protein was verified by SDS-PAGE. The VapBC26 
complex displaced by selenomethionine (SeMet) (Calbiochem, USA) was 
expressed and purified by the same procedure except that the cells, containing the 
complex displaced by SeMet were grown in M9 medium containing extra essential 
amino acids. Because there are only three methionine residues in the 
VapB26/VapC26 complex, we mutated Leu50 of VapB26 to Met50 to obtain 
sufficient phasing power. The primers used for mutation of VapB26 were as 
follows: forward, 5’−GGCGGGGCCTGGGAGATGGCCAACTGCGGTGCC-3’ 
and reverse, 5’−GGCACCGCAGTTGGCCATCTCCCAGGCCCCGCC-3’. 
Mutation was conducted using the EZchangeTM Site-Directed Mutagenesis Kit 
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(Enzynomics, Korea) according to the protocol provided by the manufacturer. For 
NMR experiments, the N-terminal (His)6-tagged VapB26 protein was expressed in 
E. coli strain BL21(DE3) using M9 medium containing 1.0 g/l [U-13C] glucose and 
1.0 g/l [15N] NH4Cl (Cambridge Isotopes Laboratory) as the sole carbon and 
nitrogen sources, respectively. The procedure for the initial purification of VapB26 
was the same as that used for the TA complex; further purification was conducted 
by size-exclusion chromatography on a HiLoad 16/60 Superdex 75 preparatory-
grade column (GE Healthcare) in a buffer consisting of 20 mM MES, pH 6, and 50 
mM NaCl. Expression of VapC26 was difficult because of its toxicity to E. coli 
(53). Therefore, as an alternative method of obtaining the VapC26 protein, limited 
proteolysis of the VapBC26 complex using pig pepsin protease (Sigma-Aldrich) 
was performed (54). Pepsin was added to the VapBC26 protein in proportion to its 
mass, and an adequate number of units which were used in accordance with the 
manufacturer’s instructions. An appropriate amount of pepsin was added to the 
purified VapBC26, and the mixture was incubated for three hours at 37˚C. The 
proteolyzed VapBC26 was further purified by size-exclusion chromatography on a 
HiLoad 16/60 Superdex 75 preparatory-grade column (GE Healthcare) under the 
same buffer condition as used in VapBC26 purification. 
 
1.2.3 Crystallization, data collection and processing 
Initial crystal screening of purified VapBC26 complex protein was conducted 
using the crystal screening 1, 2 and Index 1, 2 kit (Hamton Research) by mixing 1 
μl of protein solution at 5 mg/ml in 50 mM Tris-HCl, pH 7.9, 500 mM NaCl and 
250 mM Imidazole with 1 μl of reservoir solution. Crystals of the VapBC26 
complex were grown using the sitting-drop vapor diffusion method at 4˚C. The 
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crystallization solution for VapBC26 was 25% Tacsimate (pH 7.0). The crystals 
were directly moved to the liquid nitrogen proton beam because the crystals 
underwent extensive cracking damage when they came into contact with cryo-
protectants containing glycerol. Data were collected using the ADSC Quantum 
Q270 CCD detector at beamline 7A of the Pohang Light Source, Republic of Korea. 
Crystals of the VapBC26 complex belong to the tetragonal space group P41, with 
unit cell parameters of a = 64.35 Å, b = 64.35 Å, c = 216.96 Å, α = β = γ = 90.00˚ 
for the native VapBC26 crystal and a = 64.22 Å, b = 64.22 Å, c = 216.13 Å, α = β = 
γ = 90.00˚ for the SeMet-labeled VapBC26 crystal. The calculated total mass of the 
protein complex, including the N-terminal (His)6 tag, was 24,116.3 Da. All raw 
data were scaled and processed using the HKL2000 (55). The structure of the 
VapBC26 complex from M. tuberculosis was determined at 2.653Å resolution by 
single-wavelength anomalous dispersion using SeMet (2.545 Å for the native 
complex). Despite the slightly better resolution of the native complex, the structure 
of the SeMet crystal was as well refined as that of the native complex and the 
crystallization conditions and the space groups were equal. Therefore, further 
analysis was conducted using the SeMet data. The Met50 mutation did not affect 
protein folding. The two structures were almost identical, and the protein-protein 
interaction patterns were also equal. Detailed statistical information is presented in 
Table 1. We determined the positions of 12 selenium sites in the total asymmetric 
unit. First, PHENIX (56) was used to automatically build the total residues; the 
remaining residues were built by Coot (57) to provide the final model, which was 
refined to Rwork and Rfree  (58)  of 20.8 and 23.9%, respectively, using REFMAC 
(59). The overall geometry of the structure was validated using Molprobity (60); 
96.2% of the residues were in the favored region of the Ramachandran plot, and 
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99.9% were in the allowed region. PyMOL (61) was used to generate all figures. 
The electrostatic potential surfaces were calculated using Adaptive Poisson-
Boltzmann solver (APBS) method (62) . Secondary structure analysis was 
conducted using the 2Struc server (63). The interface area was calculated using the 
PISA server (64). Sequence alignment was performed using Clustal Omega 1.2.2 
(65) and visualized using ESPript 3.0 (66). The quality of protein purification and 
manufactured crystals were described in Figure 1. 
 
 
Figure 1. Purification and crystallization of VapBC26 from M. tuberculosis. (A) 
Column elution using engineered histidine tags. Concentration gradient is plotted at 




Table 1. Data-collection and refinement statistics for the SeMet and native 
structures. 
 (a) Data collection details. Values in parentheses are for the highest-resolution 
shell. 
Data set SeMet Native 
X-ray source 7A beamline of 
PLS, Korea 
7A beamline of 
PLS, Korea 
X-ray wavelength (Å) 0.9794 0.9795 
Space group P41 P41 
Unit cell parameters   
a, b, c ( ) 64.22, 64.22, 216.13 64.35, 64.35, 216.96 
α, β, γ (°) 90.0, 90.0, 90.0  90.0, 90.0, 90.0 
Resolution range (Å)  30-2.65 50-2.55 
Molecules per ASU 4 VapBC26 
heterodimers  
4 VapBC26  
heterodimers 
Observed reflections (>1) 619653 105433 
Unique reflections 25229  27340 
<I /(I)>  70.20 (10.87)e  34.98 (3.93)e 
Completeness (%)  99.8 (100)e  94.9 (99.1)e 
Multiplicitya 24.6 (25.4)e 3.9 (4.2)e 
Rmerge (%)b 11.3 (54.3)e  7.8 (67)e 
(b) Refinement statistics 
Data set SeMet Native 
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Rworkc (%) 20.8 22.8 
Rfreed (%) 23.9 28.4 
No. of atoms / average B factor (Å2)   
Protein 6170 / 61.0 5978 / 79.8 
Water oxygen 65 / 47.9 54 / 83.1 
RMSDf from ideal geometry   
Bond distance (Å) 0.006 0.007 
Bond angle (°) 1.25 1.27 
Ramachandran statistics   
Most favoured regions (%) 96.2 95.5 
Additional allowed regions (%) 3.7 4.4 
Residues in disallowed regions (%) 0.1 0.1 




PDB accession code 5X3T  
   
a Nobs/Nunique 
b Rmerge =  (I -  I )/   I  
c Rwork = hkl ||Fobs| - k |Fcalc||/ hkl |Fobs| 
d Rfree was calculated in the same manner as Rwork, but with 5% of the reflections 
excluded from the refinement.  
e The values in parentheses indicate the highest resolution shell. 




1.2.4 Multi-angle light scattering coupled with size exclusion 
chromatography 
We performed multi-angle light scattering (MALS) to determine the oligomeric 
states of VapB26 and VapBC26. Size-exclusion chromatography was conducted on 
a BioSep SEC-s3000 column (Phenomenex) on 1260 Infinity HPLC system 
(Agilent Technologies). The scattering data were obtained in a miniDAWN-
TREOS line for emission at 657.4 nm (Wyatt Technology) and analyzed by 
ASTRA 6.0.1.10 software (Wyatt Technology). VapB26 and VapBC26 were used at 
100 μM in the experiment. VapB26 was run in 20 mM MES pH6, and 50 mM NaCl 
as the condition of NMR spectroscopy, and VapBC26 was run in 50 mM Tris-HCl, 
pH 7.9, 500 mM NaCl and 250 mM Imidazole, the same conditions as those used 
for crystallization. All experiments were performed at room temperature.  
 
1.2.5 Inductively coupled plasma mass spectrometry 
Inductively coupled plasma mass spectrometry was conducted to confirm whether 
Mg2+ co-purified and co-crystallized with the VapBC26 complex. The crystals of 
VapBC26 used in this measurement were prepared in the same buffer as was used 
in crystallization (50 mM Tris-HCl, pH 7.9, 500 mM NaCl and 250 mM imidazole). 
An aliquot of the same buffer was used as a control. ELAN 6100, NexION 350D 
(Perkin-Elmer, USA) and argon plasma (6,000 K) were used for detection. The 




1.2.6 Isothermal titration calorimetry (ITC) measurements 
ITC experiments were performed using a MicroCal 200 (GE Healthcare) at 25˚C. 
The proteins and promoter dsDNAs were prepared in a buffer consisting of 20 mM 
MES, pH 6 and 50 mM NaCl for VapB26 and in a buffer containing 50 mM Tris-
HCl, pH 7.9, 500 mM NaCl and 250 mM Imidazole for VapBC26. The promoter 
region of VapB26 was selected as [forward – TTCGCGGCTACGCCGACAA; 
reverse – TTGTCGGCGTAGCCGCGAA], and the annealed dsDNA was 
purchased from Bioneer Innovation. A control experiment was performed with 
DNA ‘X’ [forward – GATTTTTTTTGATTTTTTT; reverse – 
AAAAAAATCAAAAAAAATC], purchased from Bioneer Innovation. DNA ‘X’ 
was annealed to form double-stranded DNA (dsDNA) by heating to 94˚C for 5 min 
and then cooling to 4˚C. Affinity experiments were conducted with the protein 
solution (10 μM, 320μl) in the cell and the promoter dsDNA solution (600 μM) as 
the injected titrant. A total of 19 injections made at 150-s intervals were used for 
data collection. The MicroCal Origin software was used for curve fitting to 
calculate the binding affinity (Kd), the enthalpy of binding ( H), the entropy of 
binding ( S) and the stoichiometry (n). The raw data were fitted using one-site 
binding. The Gibbs free energies ( G) were calculated using the standard equation 
G = H − T S. 
 
1.2.7 Electrophoretic mobility shift assay 
To distinguish the binding uniqueness of VapB26 and its promoter DNA, 
electrophoretic mobility shift assays (EMSA) were conducted for the own 
palindrome promoter sequence of the VapB26 [forward – 
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TTCGCGGCTACGCCGACAA; reverse –TTGTCGGCGTAGCCGCGAA], and 
two other palindromic sequences: ‘a’ [forward – TATTTTAATAACTTAAAAGT; 
reverse – ACTTTTAAGTTATTAAAATA], and ‘b’ [forward – 
TAATAGAATAATAAGTATCACTCCTTTA; reverse –
TAAAGGAGTGATACTTATTATTCTATTA]. The DNAs were annealed to form 
double-stranded DNA (dsDNA) by heating to 94˚C for 5 min and then cooling to 
4˚C. dsDNAs and protein were prepared in a binding buffer pH 6 consisting of 20 
mM MES and 50 mM NaCl. Varying amounts of VapB26 protein was mixed with 
each DNA to give a final volume of 10 μl and incubated for 20 min at 4˚C. The 
samples were loaded onto 0.8% agarose gels in 0.5 x TBE (45 mM Tris-borate, 1 
mM EDTA) buffer. The results were visualized using a Printgraph 2M (ATTO). 
 
1.2.8 In vitro ribonuclease assay for the addition of metals or peptides 
mimicking the binding region 
We confirmed the ribonuclease activity of VapC26 using an RNase Alert kit (IDT). 
We conducted the fluorescence quenching assay according to the protocol provided 
by the manufacturer. In this system, a fluorophore is covalently attached to one end 
of a synthetic RNA strand and is quenched by a quencher group at the other end of 
the RNA strand. If synthetic RNA containing a fluorophore-quencher pair interacts 
with ribonuclease, the synthetic RNA is digested and the quencher is released. The 
released fluorophore emits fluorescence at 520 nm upon excitation at 490 nm. The 
resulting fluorescence (RFU) was observed on a SPECTRAmax GEMINI XS 
spectrofluorometer. Using concentrations of VapC26 and VapBC26 of 2.5 μM, 
several metals, including Mg2+, Mn2+, and Zn2+ as well as peptides mimicking the 
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binding region, were examined to determine the influence of metal and peptide 
binding on the ribonuclease activity of VapC26. We first investigated the metal-
dependent ribonuclease activity of VapC26 using Mg2+, Mn2+ and Zn2+. VapC26 
was pretreated with 50mM EDTA to remove metals that may have been bound 
during purification. Its metal binding ability was then regenerated by serial dialysis 
against a buffer consisting of 50 mM Tris-HCl, pH 7.9, 500 mM NaCl and 250 mM 
Imidazole. The concentration of metal ions in the buffer was gradually increased to 
0.5 μM, 5 μM, 50 μM, 500 μM, 5 mM and 50 mM. We also designed seven short 
peptides that mimic the binding regions of VapB26 and VapC26; two of these 
mimicked the binding region of VapB26, and the other five peptides mimicked the 
binding region of VapC26. Theoretically, these peptides should compete with the 
original protein for binding to the complex (67); if the peptides are bound, the toxin 
is released from the complex, a process that can be monitored by fluorescence 
quenching. The peptides used in these experiments were purchased from AnyGen 
(Korea, www.anygen.com). 
For the mutational study of the key binding residues of VapB26 and VapC26, 
Pro46 and Tyr51 of VapB26 and Leu46 of VapC26 were mutated to alanine and 
glutamate, to diminish or remove the hydrophobic tendency. The resulting mutant 
proteins were designated P46A, P46E, Y51A, Y51E, L46A and L46E. Mutation 
was conducted using the EZchangeTM Site-Directed Mutagenesis Kit (Enzynomics, 
Korea) according to the manufacturer’s protocol. Mutated VapBC26 complexes 
were expressed and purified using the same procedures as was used for the native 
VapBC26 complex and were used in fluorescence quenching assay. The primers 
used to create these mutations are described in Table 2. 
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Table 2. Primers used for mutation. 
Primer Sequence 
P46A-Fa 5’- GGCGGCGCCAAGCCGCCGGCGCGCGGGGGTCTATATGCG-3’ 
P46A-Rb 5’- CGCATATAGACCCCCGCGCGCCGGCGGCTTGGCGCCGCC-3’ 
P46E-Fa 5’- GGCGGCGCCAAGCCGCCGGAGCGCGGGGGTCTATATGCG-3’ 
P46E-Rb 5’- CGCATATAGACCCCCGCGCTCCGGCGGCTTGGCGCCGCC-3’ 
Y51A-Fa 5’- CCGCCGCGCGGGGGTCTAGCTGCGGGTTCGGAGCCCATC-3’ 
Y51A-Rb 5’- GATGGGCTCCGAACCCGCAGCTAGACCCCCGCGCGGCGG-3’ 
Y51E-Fa 5’- CCGCCGCGCGGGGGTCTAGAGGCGGGTTCGGAGCCCATC-3’ 
Y51E-Rb 5’- GATGGGCTCCGAACCCGCCTCTAGACCCCCGCGCGGCGG-3’ 
L46A-Fa 5’- GTAGCGGAACTCGACTATGCCGTCGCCACCCGGGTAGGT-3’ 
L46A-Rb 5’- ACCTACCCGGGTGGCGACGGCATAGTCGAGTTCCGCTAC-3’ 
L46E-Fa 5’- GTAGCGGAACTCGACTATGAGGTCGCCACCCGGGTAGGT-3’ 
L46E-Rb 5’- ACCTACCCGGGTGGCGACCTCATAGTCGAGTTCCGCTAC-3’ 
a,b F and R indicate forward and reverse respectively. Enzyme sites are underlined 
above. 
 
1.2.9 NMR study of full-length VapB26 antitoxin and DNA titration 
The NMR spectrum of antitoxin VapB26 was measured on a Bruker AVANCE 
DRX 800 spectrometer. All the experiments were performed at 25˚C. The samples 
were prepared in a buffer containing 20 mM MES pH 6, and 50 mM NaCl 
containing 10% (v/v) D2O. The data were processed using NMRPipe / nmrDraw 
(68) and further analyzed by NMRviewJ (69). The data for carbonyl carbon were 
obtained through spectrum HNCO and HNCACO, and those of α/β carbon were 
acquired through the spectrum HNCA, HNCOCA, HNCACB and CBCACONH. 
Additionally, to understand the structural transition that occurs in the specific RHH 
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domain on VapB26 binding to DNA, a 19-base-pair DNA fragment from the 
upstream region (promoter DNA) of VapB26 was added to the VapBC26 complex 
as a palindromic form. The palindromic region of VapB26 was selected as [forward 
– TTCGCGGCTACGCCGACAA, reverse – TTGTCGGCGTAGCCGCGAA]; the 
annealed dsDNA was purchased from Bioneer Innovation. DNA titration was 
conducted three times during the measurement of the HSQC spectrum. The 
concentration of VapB26 was 0.4 mM in a total of three 1H, 15N-HSQC spectra, and 
the DNA concentration was varied from 0 to a maximum of 0.08mM, which was 
20% of the protein concentration. Titration of VapB26 and the control DNA ‘X’ 
was conducted in the same manner. The intensity of the chemical shift perturbation 
(CSP) was calculated by nmrViewJ. The average CSP values of 15N and 1H were 
calculated from Equation 1, where δN and δH represent the CSP values of the 
amide nitrogen and protons. 




1.3 Results  
1.3.1 Overall structure of the VapBC26 complex 
The crystal structure of the VapBC26 complex from M. tuberculosis was 
determined at a resolution of 2.653 Å. The asymmetric unit of the crystal of the 
VapBC26 complex contains four VapB26 antitoxins and four VapC26 toxins in a 
hetero-octameric assembly. The calculated molecular weight of VapBC26 was 97.5 
± 1.6 kDa, which matched the theoretical molecular weight of the hetero-octamer 
model of VapBC26 (97.0 kDa) (Figure 2). Four of the heterodimeric VapBC26 
complexes are included in the asymmetric unit. The VapB26 dimer binds two 
VapC26 monomers, and two of the VapB2C2 complexes are related to each other by 
a dyad axis. The flexible hinge loop of the antitoxin wraps the toxin as a hook, 
known as a looped arm (Figure 3A-D and Supplementary Figure 4). 
In the structure of the VapBC26 heterodimer, VapB26 binds to VapC26 via a 
deep valley formed by four α-helices (α1- α4) of VapC26 (Figure 5). Two C-
terminal segments of VapB26, Arg59-Val61 and Phe68-Glu70, adopt turns at the 
binding interface, and the Asp62, Glu63, and Leu64 residues form a 310-helix. The 
long loop between the α2 and α3 helices of VapB26 mainly contributes to the 
binding to VapC26 through hydrophobic interactions (Figure 5) involving the 
following VapB26 residues: Pro44, Pro46, Tyr51, Ala52, Pro56, Ile57, and Ala58 in 
a loop between the α2 and α3 helices; Val61, Leu64 and Leu65 in the α3 helix; and 
Phe68. The following residues in VapC26 are important for binding: Leu9, Ala10, 
Tyr11, and Phe12 in the α1 helix; Tyr45, Leu46, Val47, Val51, Ala58, and Val59 in 
the α3 and α4 helices; and Ala15, Pro17, Ile26, Leu33, Ala41, Ala67, Trp68, and 
Leu115 in the loop between the α4 and α5 helices. The aromatic residues may be 
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involved in the arrangement of the catalytic site of VapC26 and in the formation of 
the VapB26 and VapC26 dimer (Figure 5). The interfaces of the VapBC26 complex 
consist of areas of 1,174.1 Å2 (chains A and B), 1,246 Å2 (chains C and D), 998.9 
Å2 (chains E and F), and 1,080.1 Å2 (chains G and H) (64). The interface areas 
between chains E and F and between chains G and H are relatively underestimated 
because the electron density of the VapB26 antitoxin (chains E and G) is only 
shown for Val61. 
 
 
Figure 2. Size-exclusion chromatography (SEC)-MALS chromatograms showing 
the oligomeric states of VapBC26 and VapB26 in solution. (A) VapBC26 was 
anticipated to form a hetero-octamer in solution, similar to its form in the 
asymmetric unit of the crystal structure. The UV absorption at 280 nm (left axis, 
black dotted line) and the calculated molecular weight (right axis, blue dotted line) 
are plotted as a function of the elution volume. The numbers next to the red circled 
peak indicate the average molecular weight obtained using MALS. (B) VapB26 






Figure 3. Overall structures of VapBC26 and its subunits. (A) Ribbon 
representation of the VapBC26 hetero-octamer. Chains A and E are shown in red 
and chains C and G of VapB26 are shown in salmon. Chains B and F and chains D 
and H of VapC26 are shown in slate and blue, respectively. (B) Structure of the 
VapBC26 heterodimer. An arm of VapB26 covers VapC26. (C and D) Structure of 
(C) the VapC26 and (D) VapB26 dimer detached from the VapBC26 assembly. 
VapC26 displays cross-contacts between the α5 helix of one toxin monomer and 




Figure 4. Diverse point of view and 90° rotated diagrams of (A) VapBC26 hetero-








Figure 5. Heterodimeric interface between VapB26 and VapC26. (A) The residues 
participating in hydrophobic interactions are shown as stick models. The same 
colors as those used in Figure 3 are employed. The aromatic residues that exhibit 
substantial contributions to the hydrophobic interactions in VapB26 and VapC26 
are shown in pink and light green, respectively. The driving force required to 
generate the heterodimer is derived from hydrophobic interactions. 
 
1.3.2 Structure of the VapC26 toxin 
The M. tuberculosis VapC26 toxin contains seven α-helices and five β-strands. 
The structure of the VapC26 toxin adopts an α/β/α sandwich fold composed of five 
β-strands and seven α-helices in the following order: β1 (residues 1–4), α1 
(residues 5–13), α2 (residues 18–27), β2 (residues 33–36), α3 (residues 37–52), α4 
(residues 54–65), β3 (residues 68–71), α5 (residues 74–92), α6 (residues 94–108), 
β4 (residues 110–114), α7 (residues 116–124), and β5 (residues 129–134) (Figure 
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4). Four-stranded parallel β-sheets (β2-β1-β4-β5) are surrounded by five α-helices, 
with the two remaining α-helices (α3 and α4) positioned toward the outside of the 
structure. 
VapC26 forms a homodimer such that the α5 helix of one monomer contacts the 
α3 and α4 helices of the other proximal monomer and the α3 helices partially 
interact with each other in the middle of the interface. This binding is primarily 
achieved through hydrophobic interactions. Specifically, the Pro37, Tyr38, Val40, 
and Ala41 residues participate in the α3-α3 contact, and the Leu57, Leu60, and 
Ala64 residues in the α4 helix interact with Ala75, Ile78, Ala82, and Val85 in the 
α5 helix (Figure 6A). Among these residues, Ile78 is a key residue that is required 
for dimerization of the toxin, as it participates in hydrophobic interactions with 
Val40, Leu60, Ala64 and Leu70. Ile95 in the α6 helix is also involved in 
dimerization, participating in hydrophobic interactions with Val40, Ala41, and 
Leu60 (Figure 6B). Overall, more than 30 residues are involved in the formation of 
the dimer (Figure 6A). The interface of the VapC26 homodimer has an average 
area of 1,085 Å2 (1,065.1 Å2 between chains B and H and 1,104.8 Å2 between 
chains D and F).  
The active site of VapC26 is formed by the β1-α1 loop, α3, α6, the β3 loop and 
the α7 loop. The metal coordination site of VapC26 is surrounded by carboxylate 
oxygen atoms of the following four well-conserved residues: Asp4 (the N-terminus 
of the α1 helix), Glu42 (α3 helix), Asp97 (α6 helix), and Asp116 (α7 helix) (Figure 
4C). These four acidic residues comprise a negatively charged pocket at the active 
site (Figure 6D). APBS method (62) was used to calculate the electrostatic surface 
potential. Among the four VapC26 chains in the asymmetric unit, chain H clearly 
participates in metal coordination. Heterodimers consisting of chain A-chain B, 
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chain C-chain D, and chain A-chain C of VapB26 display an electron density map 
at Glu70. However, for the chain E-chain H heterodimer, chain E only displays an 
electron density map at Val61. Therefore, due to the lack of a C-terminus in chain E, 
a spatial constraint is not present in chain H, thus allowing a definite metal ion site 
to be identified. The presence of metal ions in the VapBC26 complex was 
confirmed using inductively coupled plasma mass spectrometry (ICP-MS), which 
showed that 1.73 μM Mg2+ bound to 5.0 μM of VapBC26 complex. The control 
buffer contained Mg2+ at less than 0.1 ppb (μg/kg). In addition, the ribonuclease 
activity of VapC26 largely depends on the Mg2+ concentration. Thus, Mg2+ is likely 
coordinated within the active site of VapC26. Mg2+ coordination may be mediated 
by hydrogen bonding with the Oδ1 atom of Asp4 or Asp97 (Figure 6C). We 
identified several conserved residues, including Thr5, Ser6, Asn100, and His119, 
that support the structural integrity of the active site. The Oγ1 atom of Thr5 forms a 
hydrogen bond with the Oε2 atom of Glu42, and the Oγ atom of Ser6 and the Nδ2 
atom of Asn100 form hydrogen bonds with the Oδ1 and Oδ2 atoms of Asp4. The 
Nε2 atom of His119 forms a hydrogen bond with the Oδ2 atom of Asp97. To 
illustrate the active site, a figure comparing the active sites of the four toxin chains 











Figure 6. (A and B) Hydrophobic interface of the VapC26 homodimer. The 
residues participating in hydrophobic interactions are shown as stick models. (A) 
Close-up view of the binding interface between two VapC26 monomers. More than 
30 residues participate in cross-contacts between the α5 helix of one toxin 
monomer and the α3 and α4 helices of a neighboring toxin monomer. (B) Range of 
hydrophobic forces from Ile78 and Ile98. (C and D) Analysis of the active site. 
Mg2+ is shown in yellow. (C) Fo-Fc composite omit map of Mg2+ site contours at 
3σ [calculated with PHENIX (52)]. Hydrogen bonds are shown as black dotted 
lines. Asp4, Glu42, Asp97, Asp116 and Mg2+ organize the active site. (D) The 





Figure 7. Overlay of four toxin chains. The four active sites are composed of the 
same elements, but Mg2+ is observed only in chain H. 
 
1.3.3 Structure of the VapB26 antitoxin 
The M. tuberculosis VapB26 antitoxin contains three α-helices and one β-strand 
with a topology of β1-α1-α2-α3. The four secondary structure elements correspond 
to residues 3–6 (β1), residues 10–23 (α1), residues 27–39 (α2), and residues 60–65 
(α3) in chain A and residues 4–7 (β1), residues 10–23 (α1), residues 27–39 (α2), 
and residues 60–65 (α3) in chain C. The structure features an N-terminal β-sheet, 
two adjacent α-helices and a small C-terminal α-helix (Figure 4) with a long hinge 
loop between the α2 and α3 helices. Three consecutive prolines (Pro44, Pro45 and 
Pro46) are located between the α2 helix and the long loop. Gly24, which is located 
in the short loop region between the α1 and α2 helices, forms a hydrogen bond with 
nearby residues, thereby creating a turn conformation. The C-terminal α3 helix is 
visible in chains A and C but not in chains E or G due to the lack of an electron 
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density map.  
The structure of the VapB26 antitoxin shows a clear electron density map for all 
residues in chains A and C. According to the analysis of the structure performed 
using the 2Struc server (63), chain A of VapB26 exhibits the most ordered structure. 
VapB26 consists of the following two domains: an N-terminal DNA-binding 
domain and a C-terminal toxin-binding domain.  
The two antitoxins interact with each other through their N-terminal β-strands to 
form a homodimer. The calculated molecular weight of VapB26 is 19.0 ± 0.4 kDa, 
consistent with the theoretical molecular weight of the VapB26 dimer (19.2 kDa) 
(Figure 2). The N-terminal domain of the dimer adopts an RHH motif. The average 
area of the dimeric interfaces is 1,372.3 Å2 (1,332.2 Å2 between chains E and G; 
and 1,412.4 Å2 between chains A and C). More than 30 residues of each antitoxin 
participate in dimerization. The most notable difference between the two antitoxin 
structures was observed in the N-terminal domain. The N-terminal domains of 
chains A and C are structurally well ordered, whereas the N-terminal domains of 
chains E and G are not well folded. 
The paired residues on the two β1 strands of the VapB26 dimer, including Asp2-
Leu8 and Thr4-Val6, form hydrogen bonds through their backbone atoms (Figure 
8A), resulting in the formation of antiparallel β-sheets. The main chain O atom of 
Tyr7 acts as an acceptor for hydrogen bonding with the Nε and NH2 atoms of 
Arg32 in the α2 helix. Glu11 in the α1 helix and Arg36 in the α2 helix play 
important roles in the cross stabilization between the α1 and α2 helices by 
participating in hydrogen bonds via their side chain NH and Oε atoms, which 
support dimerization (Figure 8B). In addition to the hydrogen bonds, nonpolar 
residues also contribute to formation of the dimerization interface. Residues in the 
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α2 helix, including Val30, Ile31, Ile35, and Val39, cross-interact with equivalent 
residues in the α2 helix of the proximal antitoxin (Figure 8C). In addition, Ile35 
and Val39 play important roles in the interactions with Leu12, Ala15, Val16, and 
Ala19 in the α1 helix of the adjacent antitoxin monomer. Ala28, Ile31, and Ile35 
provide additional hydrophobic interactions to Val6 in β1. Leu8 in the β1-α1 loop 
also interacts with Ile31 and Ile35 in the antitoxin (Figure 8D). 
 
Figure 8. Interfaces of the VapB26 dimer. More than 30 residues of each VapB26 
N-terminal RHH DNA-binding domain participate in dimerization. Hydrogen 
bonds are shown as black dotted lines, and residues participating in hydrophobic 
interactions are shown as stick models. (A) Hydrogen bonding networks of 
antiparallel β-sheets. (B) Hydrogen bonds in the α1 and α2 helices. (C) 
Hydrophobic interaction in the α2 helices. (D) Range of hydrophobic forces from 
Ile35, Val39, Val6, and Leu8.  
 
1.3.4 Unique aspects of the formation of the VapBC26 complex 
A search for structural homologues of VapBC26 using the DALI server (70) 
was conducted to analyze their structural similarities, and obvious structural 
differences between the VapBC26 complex and its structural homologues were 
observed.  
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In the structural homologues, the toxin binding region of the antitoxin consists 
primarily of one or two α-helices. The antitoxin-binding region of the toxin 
consists of α-helices and four antiparallel β sheets. The structures of VapB5, 
VapB15 and VapB30 include only one α-helix (VapB30) or two α-helices (VapB5 
and VapB15). VapBs from R. felis and S. flexneri have one α-helix (α2) in the 
toxin-binding region. VapB3 from M. tuberculosis displays a complete electron 
density map at the N-terminus due to the presence of a long α-helix (α3). However, 
VapB26 does not contain a specific helix in the binding region, with the exception 
of a short α-helix in the C-terminus (α3) of chains A and C. VapB26 forms a 
flexible hinge loop without any secondary structure at the binding groove, which is 
formed by the α-helices of VapC26 (Figure 9A). 
Interestingly, VapB26 does not share significant structural similarity with other 
VapB proteins, with the exception of VapB3 (37). VapB proteins do not share the 
same DNA-binding domain and the complete structures have only been resolved 
for a few VapB proteins, which are similar to VapB26. As mentioned above, 
VapB26 contains an RHH domain in its N-terminal region. The DNA-binding 
domains of other VapB proteins are normally located in the N-terminal region. 
However, VapB5, VapB15 and VapB30 from M. tuberculosis lack an N-terminal 
structure. Thus, the structures of the DNA-binding regions of these proteins are not 
available. The VapB proteins from R. felis and S. flexneri show clear electron 
density maps for the DNA-binding domain region. However, these VapB proteins 
possess a different motif, namely, a β-barrel hairpin. Among the VapB proteins with 
determined structures, only VapB3 from M. tuberculosis shares the same RHH 
DNA-binding motif as VapB26. Nonetheless, VapBC3 from M. tuberculosis does 
not show the highest structural similarity to VapBC26. Structural similarity is only 
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observed between antitoxin VapB proteins (Figure 9B). 
Like VapB26, VapB3 and FitA (71) contain a RHH DNA-binding motif in their 
N-terminal domains. For a detailed comparison with VapB26, the structural 
similarity of VapB3 and FitA was analyzed using DALI (70). The results indicated 
that VapB3 from M. tuberculosis (37) [PDB code 3H87 (chains C and D) with root 
mean square (r.m.s.) deviations of 5.4 (chain D) and 12.7 (chain C) Å, Z-scores of 
4.1-4.2 and a sequence identity of 16%] and the DNA-bound structure of antitoxin 
FitA from Neisseria gonorrhoeae (71) [PDB code 2BSQ and 2H1O (both show 
chains E, F, G, and H) with r.m.s. deviations of 6.5 (chain G of 2BSQ) and 9.2 
(chain F of 2H1O) Å, Z-scores of 4.1-4.2 and sequence identities of 15-17%] had 
low similarity (Table 3A).  
M. tuberculosis VapC26 shares structural features similar to a PIN domain motif, 
as described above. Despite the low level of sequence similarity (16−25%), the 
secondary structures of VapC proteins resemble one another to a considerable 
extent (Figure 10). The structural homologues include (i) the VapC30 toxin from M. 
tuberculosis (40) [PDB code 4XGR (chains A, C, E and G) with a r.m.s. deviation 
of 2.3 Å, Z-scores of 15.8-16.2 and a sequence identity of 22%], (ii) the VapC toxin 
from S. flexneri (42) [PDB code 3TND (chains A, C, E and G) with r.m.s. 
deviations of 2.4-2.5 Å, Z-scores of 14.2-14.3 and a sequence identity of 16%], (iii) 
the VapC15 toxin from M. tuberculosis (39) [PDB code 4CHG (chains A, B, C, D, 
E and F) with r.m.s. deviations of 2.4-2.5 Å, Z-scores of 13.7-14.1 and sequence 
identities of 24-25%], (iv) the VapC toxin from R. felis (41) [PDB code 3ZVK 
(chains A, B, C and D) with r.m.s. deviations of 2.4-2.5 Å, Z-scores of 13.7-14.1 
and sequence identity of 16%], (v) the VapC3 toxin from M. tuberculosis (37) 
[PDB code 3H87 (chains A and B) with a r.m.s. deviation of 2.5 Å, Z-scores of 
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12.1-12.3 and a sequence identity of 18%], and (vi) the VapC5 toxin from M. 
tuberculosis (38) [PDB code 3DBO (chain B) with a r.m.s. deviation of 2.7 Å, a Z-
score of 11.3 and a sequence identity of 23%]. Among these VapC structures, 
VapC3, VapC15 and VapC30 contain Mg2+, whereas VapC15 also contains Mn2+ 
(Table 3B). 
VapC contains not only conserved acidic residues but also other conserved 
residues that support the active site, as shown in Figure 10. Unlike S. flexeneri and 
R. felis, each M. tuberculosis VapC contains Ser6. However, the Tyr45 of M. 
tuberculosis VapC26 is only conserved in the VapCs of S. flexneri and R. felis. 
Other M. tuberculosis VapCs have phenylalanine or another amino acid residue at 
the same position. Phe120 is conserved in every VapC in the figure except the 
VapC15 of M. tuberculosis. In addition, the fourth conserved acidic residue, 
Asp117, shows slight flexibility, and may be glutamate or aspartate. This flexibility 










Figure 9. Comparison of the structures of the VapBC complexes (A) and VapB 
antitoxins (B) with their homologues. (A) The complete structures of M. 
tuberculosis VapBC3 and VapBC from R. felis and S. flexneri are shown; other 
known complexes lack a considerable moiety of the antitoxin. (B) VapB from R. 
felis and S. flexneri forms a β-barrel hairpin motif. VapB3 from M. tuberculosis 
forms an RHH N-terminal domain similar to that of VapB26, but the toxin-binding 
domain contains more α-helices than that of VapB26. 
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Figure 10. Sequence alignment of VapC proteins from M. tuberculosis, S. flexneri 
and R. felis. The known secondary structure elements of the proteins are shown 
above the alignment. Identical and similar residues are highlighted in red and 
yellow, respectively. Conserved residues are indicated by red circles, and the 
residues participating in the stabilization of active sites are indicated by blue circles. 
VapC proteins are listed in order of their structural homology with VapC26. The 






Table 3. Structural comparisons with many parameters 







VapB3 (M. tuberculosis) 3H87 5.4 4.1 16% 
FitA (N. gonorrhoeae) 2BSQ 6.5 4.1 15% 
B. Structural homologs of VapB26 
Name PDB 
 code 
r.m.s.d Z-score Sequence  
identity 
VapC30 (M. tuberculosis) 4XGR 2.3 15.8 22% 
VapC (S. flexneri) 3TND 2.4 14.2 16% 
VapC15 (M. tuberculosis) 4CHG 2.4 13.7 24% 
VapC (R. felis) 3ZVK 2.4 13.7 16% 
VapC3 (M. tuberculosis) 3H87 2.5 12.1 18% 
VapC5 (M. tuberculosis) 3DBO 2.7 11.3 23% 
 
1.3.5 Characterization of the interaction between VapB26 and promoter 
DNA 
DNA-binding motifs in proteins are largely categorized into the following four 
groups: helix-turn-helix (HTH) (72), RHH (73), AbrB-type looped-hinge-helix (74), 
and the YefM type of three antiparallel β-strands and two helices (75). Structural 
studies have revealed that VapB26 contains an RHH DNA-binding motif. The 
functional unit of VapB26 consists of a tight, stable antiparallel β-sheet dimer that 
binds to DNA. The β-strand and the two subsequent helices (the first and second α-
helices) are the basic components of the RHH superfamily. In the structure of DNA 
bound CopG, which has RHH domain (PDB code 1B01) (76), the electrostatically 
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positive portion of the two α-helices faces the phosphates of the DNA backbone 
(Figure 11). Antiparallel β-sheet dimer binds to the major groove of the DNA and 
the two helices anchor the RHH domain to the DNA, allowing the protein to 
interact optimally with the DNA (73). N-terminus of α2 contacts with DNA 
phosphate backbone and the loop between α1 and α2 allows the correct positioning 
of α2. VapB26 is predicted to have dimer functional unit as RHH2 (73). 
Isothermal titration calorimetry (ITC) was used to estimate the binding affinity 
of VapB26 to promoter DNA. As shown in Figure 12A, the binding titration curve 
displays a typical hyperbolic form. The promoter DNA-binding reaction of VapB26 
is exothermic and enthalpically driven, with thermodynamic parameters of -51.8 ± 
6.3 kcal mol-1 ( H) and -146 cal mol-1 deg-1 ( S). The equilibrium dissociation 
constant (Kd) for the binding of VapB26 to DNA was measured as 4.69 ± 0.81 μM. 
The calculated stoichiometry (n) measured in the experiment was 1.1 ± 0.1, 
indicating that the VapB26 homodimer interacts with DNA. 
VapB26 is capable of binding to its upstream promoter DNA. Experimentally 
obtained values show a hydrophilic effect derived from the formation of hydrogen 
bonds between VapB26 and the promoter DNA (77). In our study, calorimetric 
trials were also performed in the absence of VapB26 under the same experimental 
conditions. No thermal changes were observed in the injections during the entire 
experiment. In addition, an ITC experiment using control DNA ‘X’ showed no 
affinity of VapB26 for this DNA (Figure 13A). 
To confirm the binding specificity of VapB26, an EMSA experiment was 
conducted using the palindromic DNA of VapB26 and two other palindromic 
sequences. The DNA concentration was fixed at 0.01 mM, and the protein 
concentration was increased from 0 to 0.8 mM. As the amount of added protein 
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increased, the shifted band corresponding to the DNA-protein complex increased 
noticeably in the samples containing VapB26 promoter DNA (Figure 12B). No 
band shifts were observed in the other samples. 
 
 
Figure 11. Predicted conformation of VapB26-DNA interaction, showing the 
electrostatic potential surface. APBS method was used to calculate the electrostatic 
potential. (A) The structure of DNA bound CopG and its electrostatic potential 










Figure 12. ITC assay and EMSA of VapB26 and the promoter DNA. (A) The 
binding curve of titration indicates that VapB26 is capable of binding to its 
upstream promoter DNA. (B) Upper: EMSA experiment testing the binding of 
VapB26 to its own promoter DNA. Middle: EMSA experiment testing the binding 
of VapB26 to another palindromic DNA ‘a’. Lower: EMSA experiment involving 
VapB26 and one more different palindromic DNA ‘b’. The concentrations of 
protein and DNA in each lane are indicated. The results indicate the gradual 
formation of DNA-protein complexes only between VapB26 and its own promoter 
DNA as the ratio of protein to DNA is increased. As DNA binds to a large amount 





Figure 13. ITC assay of VapB26 with control DNA and of VapBC26 with promoter 
DNA. The parameters could not be calculated. (A) ITC assay of VapB26 and 
control DNA, showing no interaction. (B) ITC assay of VapBC26 and promoter 
DNA in a buffer containing 500 mM NaCl and 250mM imidazole. (C) ITC assay 
of VapBC26 and promoter DNA in a buffer containing 400 mM NaCl. 
 
1.3.6 Metal-dependent ribonuclease activity of VapC26 
We performed assays of the RNAse activity of VapC26 using fluorescent RNA 
substrates. When these substrates are cleaved, they emit fluorescence in proportion 
to the amount of the substrate cleaved by VapC26. The fluorescence data are shown 
in Figures 14A and B, and the data showing the structural integrity of VapC26 are 
shown in Figure 15A. Mg2+ and Mn2+ significantly increase the enzymatic activity 
of VapC26 as the metal concentration was increased up to 5 mM, whereas the 
influence of Zn2+ on the cleavage of the RNA molecules was is negligible. The 
RNase activity decreased at metal ion concentrations greater than 5 mM. At 50 mM 
Mg2+ and Mn2+, VapC26 activity was relatively well maintained in the presence of 
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Mg2+, but approximately half of the VapC26 activity was lost in the presence of 50 
mM Mn2+. Thus, VapC26 activity is saturated in the presence of approximately 5 
mM Mg2+, but Mn2+ concentrations greater than 5 mM destroy the VapC26 
structure.  
The ribonuclease activities of PIN domain proteins, such as VapC toxins, are 
strongly dependent on the presence of divalent metal ions. VapC proteins 
commonly bind Mg2+ or Mn2+ as cofactors in their catalytic sites, which consist of 
three or four conserved acidic residues, including Asp or Glu. However, as shown 
by structural and experimental studies, only three VapBC complexes obtained from 
M. tuberculosis exhibit metal-dependent ribonuclease activity. VapC3 and VapC30 
from M. tuberculosis contain Mg2+ in their active sites, and VapC15 from M. 
tuberculosis contains both Mg2+ and Mn2+ in its active site (37,39,40). Based on our 
results, we concluded that Mg2+ or Mn2+ is required for optimal catalytic activity of 
VapBC26. Moreover, Mn2+ tends to destroy the structure of the protein, resulting in 
the preferential presence of Mg2+ in VapBC26 protein. 
In order to understand the structural and functional implications of the active 
site, we superimposed the four conserved active site residues of VapC15 toxin from 
M. tuberculosis (PDB code 4CHG), VapC26 toxin from M. tuberculosis (PDB code 
5X3T), VapC30 toxin from M. tuberculosis (PDB code 4XGR), and VapC toxin 
from S. flexneri (of PDB code 3TND), which are indicated by red circles in Figure 
9 (Figure 14C). The superposition shows a good fit of three conserved residues, but 
the location of fourth conserved residue Asp116 from VapBC26 is remote from 
corresponding residues of other structures. First metal ions are observed in three 
VapC toxin from M. tuberculosis but second metal ions are only observed in 




Figure 14. In vitro ribonuclease activity of M. tuberculosis VapC26 and 
comparison of active sites with homologs. When a synthetic RNA containing a 
fluorophore-quencher pair binds to VapC26, the RNA is digested and the quencher 
is removed. The released fluorophore generates fluorescence (A and B) 
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Fluorescence measurements, as a function of time, following the addition of Mg2+ 
and Mn2+. Based on the results, Mg2+ and Mn2+ are essential for catalytic activity. 
VapC26 was treated with EDTA prior to the assay to remove metal ions. Various 
concentrations of Mg2+ and Mn2+ were prepared, and 40 units of RiboLockTM 
(Thermo Scientific) RNase inhibitor was used to prevent contamination. The 
control contained 50 mM MgCl2 (or 50 mM MnCl2), 50 mM Tris-HCl (pH 7.9), 
500 mM NaCl, 250 mM Imidazole, and 40 units of RiboLockTM (Thermo Scientific) 
RNase inhibitor. Each experiment was performed in triplicate. (C) Superposition of 
conserved residues in active sites of VapC26 and its homologs. Residues and metal 




Figure 15. Purity and structural integrity of VapC26 and ribonuclease activity of M. 
tuberculosis VapBC26. (A) Left: SDS-PAGE of the TA complex of VapBC26 (left) 
and purified VapC26 (right). Right : Circular dichroism (CD) data of VapC26, 
showing the maintenance of structural integrity. (B), (C) Ribonuclease activity of 
M. tuberculosis VapBC26 measured using the promoter DNA and the VapB26 
- 43 -
mimic peptide ‘PPPRGGLYAGSEPIA’. Fluorescence measurements, as a function 
of time, for VapBC26 in the presence of peptides and DNA. Forty units of 
RiboLockTM (Thermo Scientific) RNase inhibitor were used to prevent 
contamination. VapC26 was treated with EDTA prior to the assay to remove metal 
ions. The negative control contained 50 mM Tris-HCl, pH 7.9, 500 mM NaCl, 250 
mM imidazole, and 40 units of RiboLockTM (Thermo Scientific) RNase inhibitor. 
VapC26 in a solution containing 5 mM Mg2+ was used as a positive control. Each 
experiment was performed in triplicate. Neither peptides nor DNA contributed to 
increases in fluorescence. Other VapB26-mimicking peptides also did not have an 
impact on fluorescence.  
 
1.3.7 Influence of peptides on the RNase activity of VapC26 
We designed seven peptides as potential inhibitors of the interaction between 
VapB26 and VapC26. These peptides mimic the binding interface of VapB26 and 
VapC26. The sequences of peptides two and five correspond to those of portions of 
the binding regions of VapB26 and VapC26, respectively. Theoretically, these 
mimicking peptides could compete with their binding partners VapB26 and 
VapC26 and thereby preventing the formation of the TA complex (67). If the 
peptides bind with high affinity, free VapC26 would be more predominant, 
resulting in increased RNase activity. The sequences of the seven peptides are 
presented in Table 4. 
As expected, the ribonuclease activity of the M. tuberculosis VapBC26 complex is 
weak compared to that of VapC26. As a result of competition with the peptide, the 
ribonuclease activity of VapBC26 at 2.5 μM increases. We did not observe an 
- 44 -
increase in the fluorescence of VapBC26 following the addition of VapB26-
mimicking peptides at peptide-to-protein ratios of 1:1, 10:1, or 100:1 (Figure 15). 
However, we confirmed that VapC26-mimicking peptides act as inhibitors (Figure 
16A and Figure 17). VapBC26 showed increased activity following the addition of 
the α4-mimicking peptide compared to the addition of the α3-mimicking peptide 
and of peptides corresponding to both helices.  
We conducted an additional experiment in which we fixed the concentration of 
the α4-mimicking peptide at 2.5 μM and increased the concentration of VapBC26 
from 0.625 μM to 20 μM. The plot of the relative fluorescence units (RFU) for 
concentrations of VapBC26 greater than 10 μM was not markedly different from 
the graph for 10 μM VapBC26 (Figure 16B). 
Based on our ITC data, VapB26 showed affinity for DNA. In our NMR titration 
experiments, which are presented in the next section, the promoter DNA of VapB26 
caused a chemical shift in the α3 helix residues of VapB26 that are involved in 
VapC26 binding. Therefore, we titrated VapBC26 with an increasing amount of 
promoter DNA to examine whether DNA weakens the interaction between VapB26 
and VapC26. However, we did not observe increased fluorescence with the addition 
of the promoter DNA at DNA-to-protein ratio of 1:10, 2:10, 3:10, 5:10 or 20:10 
(Figure 15C).  
To verify that the key binding residues are necessary for the interaction between 
VapB26 and VapC26, an additional mutational experiment was conducted. Based 
on the interface, Pro46 and Tyr51 of VapB26 and Leu46 of VapC26, which occupy 
hydrophobic networks with multiple counterparts, were selected. The selected key 
residues were mutated to alanine and glutamate to diminish or remove the 
hydrophobic tendency. Then, 10 μM of the α4-mimicking peptide was added to the 
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mutated complexes. The results show that Tyr51 of VapB26 had the greatest 
influence on interaction between VapB26 and VapC26, resulting in the emission of 
more fluorescence (Figure 16C). To confirm the statistical validity of this result, t-
test was performed for Y51A and wild type, Y51E and wild type. The p-values 
were calculated as 0.004 for Y51A and wild type, and 0.003 for Y51E and wild 
type. Thus it was confirmed that the distribution of variance of each data was 
different. To support these results, VapB26 antitoxin, VapC26 toxin, native 
VapBC26 complex, Y51E complex, which is expected to have the greatest impact 
on interaction, and α4-mimicking peptide added each complexes were loaded into 
Superdex 75 10/300 prepacked column (GE Healthcare) and chromatograms were 
collected. The peptide added VapBC26 complexes showed peaks at different 
positions from the original peak corresponding VapB26 and VapC26, and the 
peptide added Y51E complex contained more disassembled proteins than the 
peptide added native complex (Figure 16D). Calculated area corresponding to 
VapC26 of α4-mimicking peptide added Y51E complex was 15.42 % higher than 
that of α4-mimicking peptide added native complex, which is well consistent with 
15.07 % increased fluorescence of Y51E in Figure 16C. The volume of injected 
protein was 100 μl and the concentration of proteins and α4-mimicking peptide 
concentration was 200 μM and 1 mM, respectively.  
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Figure 16. Ribonuclease activity of M. tuberculosis VapC26 measured using a 
VapC26 α4-mimicking peptide and experiments using mutants. (A and B) The 
pretreatment was performed as described in Figure 14, and 5 mM Mg2+ was added 
to each well for optimal activity. (A) The concentration of VapBC26 was fixed at 
2.5 μM, and the concentration of peptide was increased from 2.5 μM to 1 mM. The 
peptide inhibited the binding of VapB26 to VapC26 by approximately 50% at 10 
μM and by 80% at 200 μM. (B) The concentration of the α4-mimicking peptide 
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was fixed at 2.5 μM, and the concentration of VapBC26 was increased from 0.625 
to 20 μM. Based on the data, 2.5 μM peptide interacts with approximately 10 μM 
VapBC26. The experiment was performed in triplicate. (C and D) Comparison of 
the ribonuclease activity of native VapBC26 and mutated VapBC26. Pretreatment 
was performed as described in the legend to Figure 14A and B. (C) 10 μM of the 
α4-mimicking peptide was added to the mutated complex (P46A, P46E, Y51A, 
Y51E, L46A and L46E). Native VapBC26, which shows approximately half the 
activity of VapC26 in the presence of 10 μM of the α4-mimicking peptide, was 
used as a reference for comparison. The concentration of each VapBC26 mutant 2.5 
μM was the same as that of the native VapBC26 complex. RFU obtained with the 
reference was taken as 100%. Tyr51 of VapB26 showed the largest effect on the 
binding of VapB26 and VapC26. Error bars represent the standard deviation of 
three replicate reactions. (D) Size exclusion chromatography of various proteins. 










Figure 17. Initial test of the RNase activity of M. tuberculosis VapBC26 in the 
presence of toxin-mimicking peptides (α3, α4 and both α3 and α4). When a 
synthetic RNA containing a fluorophore-quencher pair binds to VapC26, the RNA 
is digested and the quenching is removed. The released fluorophore generates 
fluorescence. The test was performed approximately 10 times on a smaller scale 
than in the standard experiments described in the main text to identify the most 
effective peptide. As shown in the diagram, the peptide that mimics the α4 helix 












Table 4. Residues used to create mimicking peptides 




PPPRGGLYAGSEPIA (44-58) VapB26 Coil between α2 
and α3 
VDELLAGF (61-68) VapB26 α3 
ALLAYFDAAEP (7-17) VapC26 α1 
PYVVAELDYLVATRVG (37-52) VapC26 α3 
DAELAVLRELAG (54-65) VapC26 α4 
YLVATRVGVDAELAV (45-59) VapC26 Some moieties 
of α3 and α4 
PYVVAELDYLVATRVGVDAELAVLRELAG 
(37-65) 
VapC26 Whole α3 and 
α4 
 
1.3.8 DNA-binding site of VapB26 
In type II TA systems, the antitoxin alone or in complex with toxin typically 
interacts with its corresponding promoter DNA, repressing the transcription of the 
TA operon. Therefore, the DNA-binding properties of the antitoxin are important 
for the regulation of TA systems. We characterized the interactions between 
specific residues in VapB26 and the promoter DNA using NMR titration 
experiments.  
We assigned the peaks to the VapB26 backbone, and 69 out of 71 cross-peaks 
(97.2%) observed in the 1H-15N heteronuclear single quantum correlation (HSQC) 
spectra were assigned to individual residues of VapB26, with the exception of 
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Pro44 and Pro45 in the proline bridge. Based on the assigned backbone 1H and 15N 
resonances, we monitored the residues showing changes in the chemical shifts or 
resonance broadenings upon binding to DNA. We compared the HSQC spectra of 
VapB26 (0.4 mM) in the absence and presence of increasing concentrations of 
promoter DNA (0.04 and 0.08 mM). DNA concentrations greater than 0.08 mM 
caused few additional changes in the chemical shifts of VapB26, suggesting that 
the DNA-binding site of the protein is saturated at concentrations above 0.08 mM. 
These comparative spectra are shown as an overlay in Figure 18C and D (dotted 
square in the center of the figure). 
The shifts in the peaks observed in the spectra indicate that the VapB26-DNA 
interaction is achieved in a fast exchange on the NMR time scale, which is 
typically observed when molecules bind with a low to moderate affinity. We 
calculated the combined 1H and 15N chemical shift perturbation (CSP) values of 
VapB26 in the presence of 0.08 mM DNA using equation 1 shown in the Materials 
and Methods section to quantify the peak shifts. These values are plotted as a 
function of VapB26 residues (Figure 18A).  
The CSP values of the residues belonging to the RHH DNA-binding domain were 
large. Residues belonging to the α1 helix (Glu11, Leu12, Lys13, Ala14, and Ala15) 
showed an even distribution of CSP values. Some residues in the α2 helix (Glu27, 
Ala28, Arg32, Ile35, and Val39) exhibited significant changes in their chemical 
shifts. Glu27, Ala28, Ile35 and Val39 located in the α2 helix showed CSP values 
greater than 0.07. The average CSP value of β1 residues (Asp2-Tyr7) was less 
(0.021) than the CSP values of residues in the α1 (0.038) and α2 helices (0.045). 
Interestingly, moderate CSP values were observed for the residues corresponding to 
the α3 helix in the C-terminal domain (average CSP: 0.023) in the structure of the 
- 51 -
complex, which is involved in binding to the VapC26 toxin. 
As shown in our fluorescence assay, the binding of DNA to VapBC26 did not 
disrupt binding of VapB26 and VapC26, when VapB26 and VapC26 were already 
bound. Based on the observed changes in the CSP values of the residues in the α3 
helix, it is estimated that DNA binds directly to the N-terminal domain of VapB26. 
However, the binding of DNA to VapB26 affects the conformation of the α3 helix 
of VapB26, indicated by the moderate CSP values and the large peak intensity 
change. Because this region is a toxin-binding region, the binding of DNA to 
VapB26 might also have an effect on the binding of VapC26 to VapB26. 
The results of the titration experiment were consistent with the ITC data. 
According to the Kd determined in the ITC experiment, the binding between 
VapB26 and DNA is not strong; thus, the binding mode between VapB26 and DNA 
is expected to show fast exchange. This result is highly consistent with the 
observed peak movements in the spectra of VapB26 titrated with DNA. Upon 
titration with DNA, the spectra of VapB26 showed peak broadening and a shift but 
not a peak split.  
The secondary structure of VapB26 in solution was derived from the program 
TALOS+ (78) using the assigned chemical shift values (Table 5). VapB26 adopts a 
conformation that includes two α-helices (α1 and α2) and one short β-strand; this is 
partially consistent with the structure of VapB26 in the VapBC26 complex. Val6 
and Tyr7 at the N-terminus adopt a β-strand conformation. However, the presence 
of the α3 helix (residues 60-67) in VapC26-bound VapB26 is not consistent with an 
unfolded structure of the corresponding region of VapB26 alone. Because this 
region participates in toxin binding, helix formation may be coupled to toxin 
binding. 
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In addition, the overall resonance broadenings of VapB26 residues may have 
occurred due to the formation of a transient complex between VapB26 and DNA, 
increasing the transverse relaxation rate of the protein. However, considerable 
resonance broadenings for specific residues are mainly attributable to their 
interaction with DNA in an intermediate exchange on the NMR time scale. The 
residues in the DNA-binding region showed low intensities and peak disappearance 
due to the decreased transverse relaxation. Changes in peak intensity (I) upon DNA 
binding also indicate protein recognition (79). The ratios of peak intensities for 
DNA-bound and free VapB26 (IDNA/I0) are plotted against the VapB26 residues to 
quantify the resonance broadening effect (Figure 18B). Severe resonance 
broadening upon binding to DNA is mainly observed for the α1 and α2 helices. In 
particular, four residues, namely Glu27, Ala28, Arg32 and Ile35, located in the α2 
helix show the largest reductions in peak intensities of up to approximately 95%, 
suggesting that these residues are key residues involved in the interaction between 
VapB26 and the promoter DNA. These results are in highly consistent with the CSP 
data showing that the α1 and α2 helices of VapB26 are involved in the interaction 
with DNA. Reduced peak intensities of several residues in the C-terminal region 
may be explained by changes in the dynamics from fast motion to intermediate 
motion when VapB26 binds to DNA. 
NMR titration was also conducted using control DNA ‘X’. In contrast to the 
results obtained using promoter DNA, the results showed almost no peak shifts. 
The ratios of peak intensities were well maintained with the addition of ‘X’ (Figure 
19). 
Based on these data and on the NMR results, we characterized the DNA-binding 
region of VapB26 and identified the changes in the VapB26 structure upon binding 
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to VapC26. The regions showing relatively high CSP values and peak intensity 





Figure 18. NMR titration of VapB26 and its promoter DNA. (A and B) Secondary 
structure elements based on the TALOS+ analysis are presented above the plots. (A) 
The chemical shift perturbation of each residue in the presence of 0.08 mM 
promoter DNA. The residues in the N-terminal RHH DNA-binding domain (Glu11, 
Leu12, Lys13, Ala14, Ala15, Glu27, Ala28, Arg32, Ile35 and Val39 in the α1 and 
α2 helices) show CSP values greater than 0.05 (blue dotted line). (B) Relative peak 
intensity compared to that of the DNA-free form. The peak intensities for Glu27, 
Ala28, Arg32, and Ile35 in the α2 helix exhibited the largest decreases of less than 
5% compared to the peak intensity of the free form. (C) Overlay of 2D 1H-15N 
HSQC spectra of 0.4 mM VapB26 with increasing ratios of added DNA. VapB26 
with no DNA is shown in light blue, VapB26 with 0.04 mM DNA is shown in 
medium blue, and VapB26 with 0.08 mM DNA is shown in dark blue. The red 
arrows show the peak shift direction. The Glu27, Ala28, Arg32, and Ile35 peaks 
disappeared during the interaction with DNA (inverted red triangle). The 
unassigned residues are not shown. (D) Expanded views of the peak overlap region 
highlighted with a black dotted square in (C). The spectrum shows DNA/protein 




Figure 19. NMR titration experiment of VapB26 and control DNA ‘X’. Overlay of 
2D 1H-15N HSQC spectra of 0.4 mM VapB26 with increasing ratios of added DNA 
‘X’. VapB26 with no DNA ‘X’ is shown in light green, VapB26 with 0.04 mM 
DNA ‘X’ is shown in medium green, and VapB26 with 0.08 mM DNA ‘X’ is 
shown in dark green. The peaks that displayed distinct changes during the 
interaction of VapB26 with promoter DNA are indicated. None of the indicated 
peaks show distinct changes in both the peak shifts and the intensity ratio in this 






Figure 20. Schematic representation and surface representation of VapB26 mapped 
with CSP values (red) and intensity-related values (blue). The residues are colored 
with a gradient indicating their CSP values and intensity decrease upon the addition 
of promoter DNA. As predicted, large CSP values were observed for the residues 
belonging to the RHH DNA-binding domain, particularly residues in the α1 and α2 
helices. Moreover, large decreases in peak intensities were observed for residues in 
the α1 and α2 helices. The β1 region in the crystal structure showed relatively low 










Table 5. Predicted secondary structures with confidence scores offered by Talos 
based on the backbone-assigned amino acid sequence of VapB26 
Sequence M D K T T V Y L P D 
Predicted secondary structure L L L L L E E L L H 
Confidence score 0 3 8 9 6 5 7 5 8 7 
E L K A A V K R A A R Q R G V S E A Q V 
H H H H H H H H H H H H H L L L H H H H 
9 9 9 9 9 9 9 9 9 9 9 8 2 7 5 7 8 9 9 9 
I R E S I R A A V G G A K P P P R G G L 
H H H H H H H H L L L L L X X L L L L L 
9 9 9 9 9 9 9 5 4 8 8 8 9 0 0 9 9 8 7 4 
Y A G S E P I A R R V D E L L A G F G E 
L L L L L L L L L L L L L L L L L L L L 




H = helix, E = strand, L = coil, X = unassigned two prolines. 





1.4.1 Insights into the unique structure of the VapBC26 complex 
Based on the complete analysis of the VapBC26 structure, the binding affinities 
of VapB26 and VapC26 may be stronger than those of other VapBC structures. 
Due to their binding affinity for the toxin via the binding domain, the N-terminus-
lacking structures of VapBC might have lower steric hindrance than the complete 
structure. The average binding interface area of VapBC30 (1,002.1 Å2) is 
considerably smaller than the average area of the complete chains of VapBC26 
(1,255.05 Å2), and the average G (kcal/mol) for VapBC26 (-15.9) is considerably 
different from the values for VapBC5 (-12.0) and VapBC15 (-12.9), calculated by 
PISA server (64). 
This binding force of VapBC26 is mainly attributed to hydrophobic interactions. 
The proportion of hydrophobic interactions in the total interactions is higher than 
that of other VapBC complexes. Ring-type amino acids, such as prolines and 
aromatic amino acids, including phenylalanine, tryptophan and tyrosine, comprise 
a large proportion of hydrophobic interactions. The abundant aromatic amino acids 
in VapBC26 may largely contribute to maintaining the structural integrity and 
proper function of the protein (80). The strong hydrophobic force derived from the 
ring results in strong binding (81). Pro44, Pro46, Tyr51, Pro56 and Phe68 of 
VapB26 and Tyr11, Phe12, Pro17, Tyr45 and Trp68 of VapC26 participate in the 
interaction between VapB26 and VapC26; together, these residues represent more 
than 30% (10/29) of the total number of amino acids that participate in the 
interaction between VapB26 and VapC26.  
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The proline bridge (Pro44, Pro45 and Pro46) in VapB26 plays a supporting role at 
the beginning of the toxin binding region. Proline is a strong disruptor of secondary 
structure in both α-helices and β-strands due to its spatial hindrance, which can 
prevent the formation of secondary structure. Moreover, the proline bridge of 
VapB26 serves as a boundary for the DNA-binding and toxin-binding moieties, as 
it is located in the middle of the disordered region (82-85). Tyr45, Pro37 and Tyr38 
of VapC26 participate in binding to the adjacent VapC26 protein. In addition, 
Tyr45 and Phe120 of VapC26 are involved in maintaining protein functions by 
stabilizing the active site of the VapC26 protein (86). Peptides, including Tyr45 in 
the α3 helix, show less activity than other peptides (Figure 17).  
In the case of Haemophilus influenza VapC1, mutation of 17 amino acid residues 
in VapC1 showed that these residues do not play essential roles in the interaction of 
the protein with its cognate antitoxin (87). However, in our study, although single 
mutations of Pro46 and Tyr51 in VapB26 and of Leu46 in VapC26 did not totally 
disrupt the interaction required to form VapBC26, the slightly increased 
ribonuclease activity of the mutated VapBCs and decreased complex form of Y51E 
compared to native complex when of α4-mimicking peptide was added in size 
exclusion chromatography supports a role for these hydrophobic residues in 
forming the VapBC26 interface. 
 
1.4.2 DNA-binding mechanism of VapB26 and the ensuing 
conformational change 
According to studies of FitAB from N. gonorrhoeae, VapBC2 from R. felis and 
VapBC from S. flexneri (41,42,71), the β1 residues of VapB26 mediate the contact 
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between VapB26 and DNA but do not directly participate in the binding interface. 
Upon binding to DNA, the conserved residues in β1 recognize DNA, key residues 
in the two helices directly contacting DNA, and residues in the α2 helix bind to the 
phosphate backbone of DNA at the major groove (73). Alterations in the N-
terminal region induced by the interaction with DNA are maintained by two 
flexible loops between β1 and α1 as well as between α1 and α2. 
In our study, the notable chemical shift perturbation and decrease in the intensity 
of residues in the α1 and α2 helices revealed that the Glu27, Ala28, Arg32, Ile35 
and Val39 residues are important for binding to DNA. In this interaction, the 
promoter site is located in close proximity to RNA polymerase, and transcription is 
repressed. Therefore, the normal biological functions of bacteria are blocked (88). 
Promoter DNA is bound by VapBC26 in an extracellular environment, but as M. 
tuberculosis enters epithelial cells, DNA is released and transcription is initiated 
(71). Our identification of the residues required for the interaction between 
VapB26 and promoter DNA will help elucidate the transcriptional repression 
mechanism and downstream biological actions. 
VapB proteins with a β-barrel hairpin domain do not form antiparallel β-sheets 
until they bind to DNA. Upon interacting with DNA, the β-strands pack tightly to 
form a complete DNA-binding domain (42). Proteins, such as HU, have flexible β-
arms and bend inward when binding to DNA (89). However, VapB26 naturally 
forms a homodimer in solution, as shown in our multi-angle light scattering 
(MALS) data (Figure 2), and the RHH domain of VapB26 was confirmed by 
analyzing the crystal structure of the DNA-free protein. Thus, VapB26 does not 
undergo dramatic conformational changes in the N-terminal region before and after 
DNA binding. 
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In contrast, the TALOS+ (78) secondary structure prediction showed that the 
binding of DNA to VapB26 generates conformational and dynamic changes in the 
α3 helix of VapB26, unlike the VapC26-bound structure. VapC26 does not directly 
participate in the interaction with DNA. However, for FitAB, HipAB and MazEF, 
the binding affinity of VapB26 to DNA is increased when the antitoxins bind the 
toxins (71,90,91). VapC26 might thermodynamically contribute to the interaction 
between VapB26 and DNA by forming a complex with VapB26 and stabilizing the 
N-terminal-binding domain of VapB26 (92). Similarly, transcription factors 
undergo conformational changes that increase structural stability or substrate 
specificity by induced fit or local folding (93-95). Studies of the relationship 
between the conformational changes that occur in VapB26 and its binding to 
VapC26 or DNA would be interesting.  
Although we were unable to calculate parameters for the interaction between 
VapBC26 and promoter DNA due to the poor stability of the protein under low salt 
conditions (Figures 13B and C), the C-terminal toxin-binding domain of VapB26 is 
affected by DNA binding according to our NMR data. Importantly, VapB26, 
VapC26 and DNA have a mutual relationship (96,97). 
 
1.4.3 Mechanism of the in vitro ribonuclease activity of VapC26 
According to our experimental data, the ribonuclease activity of VapC26 was only 
observed when VapC26 was released from VapB26. EDTA-treated VapC26 did 
not display ribonuclease activity. Thus, Mg2+ and Mn2+ are essential for VapC26 to 
block translation by degrading the RNA and inhibiting bacteria growth. Because 
Mg2+ is smaller than Mn2+, Mg2+ has a strong tendency to mediate water-mediated 
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interactions with the active site. Mg2+ activates the water molecule for nucleophilic 
attack and stabilizes the active site. This mechanism is shared by other nucleases 
and ribonucleases (98-100).  
The C-terminal α3 helix of VapB26 may affect the position of Mg2+ and Mn2+, 
which are essential for ribonuclease activity. The α3 helix of VapB26 precisely 
blocks the putative RNA-binding site of VapC26 and Mg2+ binding by covering the 
active site. When VapB26 is not bound to VapC26, Mg2+, the RNA substrate and 
the active site of VapC26 form an active complex (37,39,44,87,101). 
Although VapC toxins share structural similarity of active site, they could 
recognize different targets. VapCs from S. flexneri, Salmonella typhimurium, and 
Leptospira interrogans cleave tRNA in the acticodon stem loop (ASL) (49,102). In 
M. tuberculosis, VapC4, VapC11, VapC15, VapC25, VapC28, VapC29, VapC30, 
VapC32, VapC33, VapC37, and VapC39 cleave tRNA (49). VapC20 and VapC26 
cut the 23S rRNA in the sarcin-ricin loop (SRL) (47,49). On the basis of previously 
suggested mechanism of two-metal ion (103), first metal ion in VapBC system can 
accommodate phosphate hydrolysis, whereas second metal ion seems to be 
required to stabilize the conformation of active site. In the structural comparison of 
active sites with reported VapC structures (Figure 14), second metal ion is 
coordinated by 4th conserved residue. Corresponding residues of the ASL enzymes, 
VapC toxin from S. flexneri, and VapC15 and VapC30 toxins from M. tuberculosis 
showed conservation of geometry. However, the VapC26 toxin from M. 
tuberculosis, SRL enzyme exhibited different position of the 4th conserved residue. 
These structural differences of VapC toxins would cause target specificity in spite 




1.4.4 Importance of the VapBC26 system as an antibiotic target 
VapBC systems are of great importance in the study of M. tuberculosis because 
they are present in quite small numbers in other mycobacteria, compared to M. 
tuberculosis (35). Furthermore, VapBC26 has great importance as a potential 
antibiotic target. First, in the hypoxic state, VapB26 expression varies greatly (35), 
suggesting the possible importance of VapB26 in the stress state. Second, VapC26 
is a ribotoxin, cutting the SRL. SRL is the longest conserved sequence in 23s 
rRNA and is crucial for triggering of GTP hydrolysis and for the anchoring of the 
elongation factor during mRNA-tRNA translocation (50,104). In particular, sarcin 
and ricin, which actually targets the SRL, completely inactivate the ribosome. 
Third, strong growth arrest of E. coli occurs when L. interrogans VapC is 
expressed (105). Even more crucially, the expression of VapC26 strongly inhibits 
the growth of M. smegmatis (106,107). 
In conclusion, VapC26 can exhibit growth inhibition effect of target cell and act as 
an effective translation inhibitor. Therefore, the VapBC26 system is expected to 
bring about new antibiotic target and peptide inhibitor of TA interaction could be a 
potential antibiotics. 
 
1.4.5 Artificial toxin activation by inhibition of the TA complex 
We designed several VapB26 mimetic peptides in an attempt to disrupt the 
VapBC26 complex. In B. anthracis PemIK, peptide inhibitors that mimic the C-
terminal toxin-binding region of PemI influence the TA interaction (108). A 
peptide designed to mimic the backbone of MoxX also influences the TA 
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interaction (109). The active site of VapC26 interacts with the α3 helix and the C-
terminal region of VapB26, but the peptide mimicking the α3 helix of VapB26 
does not show any enzymatic activity. With respect to the disruption of the 
VapB30-VapC30 interaction by the designed peptides, VapB30 lacks the N-
terminal residues from 1-46 unlike the complete form of VapB26 (40); this may 
weaken and prevent complete binding. However, the VapC26-mimicking peptides 
show great potential as antimicrobial agents. The toxin-mimicking peptides used in 
the present study interrupted the binding of VapB26 and VapC26 by approximately 
80% or more at the highest peptide concentration. These data provide evidence 
suggesting that this peptide may represent novel pharmaceutical compound. 
The development of antibiotic drugs based on the TA systems of pathogenic 
bacteria has attracted interest, and the artificial activation of toxins is a powerful 
antibacterial strategy. For this purpose, the inhibitor molecule must bind tightly to 
the TA interaction site to disrupt the TA interaction. The VapC26-mimicking 
peptide generated in the present study shows possibility as a bactericidal agent 
based on protein (antitoxin)-protein (toxin) interaction (PPI-approaches) 
(10,110,111). We may be able to obtain a more optimized inhibitor by applying 
bio-active techniques, such as stapled peptides. Stapled peptides are stabilized by a 
hydrocarbon cross-link to form a bioactive conformation and have enhanced 
membrane permeability (112). Attaching cell-penetrating peptides (CPPs) to the 
peptide inhibitors might be considered as a way of improving the delivery of 
antibiotic peptides to appropriate target tissues, and the limited side effects of these 
peptides in vivo and in vitro and their rapid penetration into bacterial cells of CPPs 
could enhance their efficiency (113,114). In addition, various modifications can be 
attached to peptide by conjugation strategies. Combination therapy and surface 
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modulation can increase antibacterial activity and membrane permeability (115). 
Furthermore, peptide nanoparticles are economical and biocompatible for 
therapeutic applications (116).  
Adequate activation of toxins may induce trivial chronic infections by 
encouraging the formation of persister or dormant cells. Based on the experimental 






Pathogenic bacteria, such as M. tuberculosis, utilize many toxin-antitoxin (TA) 
systems to survive. TA systems are strongly correlated with bacterial physiology, 
such as gene regulation, growth arrest, survival, and apoptosis. The VapBC TA 
family is one of the most widely distributed TA families. However, crystal 
structures have only been determined for the following six VapBC TA complexes 
to date. The VapC26 toxin damages a host cell by inducing RNA degradation or 
binding to topoisomerase or ribosome. The VapB26 antitoxin is an important 
cellular components for cell maintenance and viability because it neutralizes the 
detrimental activity of its cognate toxin. The VapB26 antitoxin acts as a repressors 
that auto-regulates the transcription of the TA operon. The VapC26 toxin exhibits 
ribonuclease activity toward cellular mRNAs. 
 
In particular, we present the crystal structure of the VapBC26 complex from M. 
tuberculosis at a resolution of 2.653 Å. The structure revealed the important 
residues involved in binding to the promotor DNA and in the formation of the 
VapBC26 complex. The VapC26 toxin forms an overall α/β/α structure with four 
parallel β strands, and VapB26 adopts a ribbon-helix-helix (RHH) DNA-binding 
motif. The core residues in VapB26 that bind to DNA and the structural changes in 
VapB26 resulting from toxin binding were clarified by nuclear magnetic resonance 
(NMR). The catalytic site of VapC26 is composed of three conserved acidic 
residues that bind to Mg2+, and the ribonuclease activity of VapC26 was confirmed 
in this study. Several peptides were designed as antibiotic candidates to mimic the 
binding interface of the VapBC26 complex and thereby suppress the TA 
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interaction. This approach may contribute to the development of novel, potent 





Chapter 2. Functional details of the Streptococcus 
pneumoniae HicBA toxin-antitoxin system 
2.1 Introduction  
Streptococcus pneumoniae is gram-positive, facultative anaerobic, and significant 
human pathogenic bacteria. This bacterium causes otitis media, sinusitis, 
pneumonia and meningitis. S. pneumoniae is usually inhaled by respiratory system 
and stays in pharynx and nasal cavity to generate diseases (117,118). Glycopeptide 
antibiotics vancomycin as well as penicillin is frequently used to eradicate bacteria 
and relieve symptoms (119,120). However, in worldwide, S. pneumoniae gathered 
outstanding remark of antibiotic resistance. Unfortunately, extensive drug-resistant 
S. pneumoniae has been appeared and it shows resistance to penicillin, 
cephalosporin, macrolide, β-lactam antibiotics fluoroquinolone and even to 
vancomycin and linezolid (121-123). Nowadays, antibiotics combination therapy is 
used to get synergism, but it cannot effectively suppress the drug-resistant bacteria 
(124-126). Therefore, the development of new antibiotic candidates to eradicate S. 
pneumoniae by exploiting new therapeutic strategies is urgently needed. 
 
In the bacterial strain S. pneumoniae TIGR4, there are only six TA loci (three 
RelBE family, one phd-doc family, one HigBA family and one HicBA family) (33). 
There is a relatively small number of TA loci in S. pneumoniae, compared to other 
bacteria. For the example, Mycobacterium tuberculosis has more than 88 TA 
operons known. Action mechanisms of TA have been studied for ages but 
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physiological roles of TA have not yet been clearly elucidated (35,36,38). 
Furthermore, to date, crystal structure of HicBA TA complex has been determined 
for only one from Yersinia pestis, Protein Data Bank (PDB) code 4P78 (HicBA3), 
which lacks the C-terminal region of antitoxin (127).  
 
HicB antitoxins consist of the two functional motifs: N-terminal region that binds 
to the toxin and thereby abolishes its toxicity, and the C-terminal region that binds 
to the promoter DNA of the TA operon that auto-regulates TA operon (51,52). 
DNA-binding domain of HicB (128) forms ribbon-helix-helix (RHH) (73) or helix-
turn-helix (HTH) motives (72). HicA toxins contain double stranded RNA binding 
domain (DsRBD) (129) and exhibit ribonuclease activity (130). The active sites of 
HicA toxins contain conserved histidine residue (127,131). 
 
Here, we present the crystal structure of the HicBA complex from S. pneumoniae 
TIGR4 at a resolution of 2.30 Å. The C-terminal DNA-binding domain of HicB 
antitoxins shows a considerable structural deviation and HicA toxin has contacts 
with a curved back of the HicB antitoxin. The structure revealed the important 
residues in the formation of the HicBA complex. The core residues in HicB that 
bind to DNA and properties of DNA binding domain were clarified by nuclear 
magnetic resonance (NMR). Binding interface mimicking peptides were designed 
as antibiotic candidates to be antimicrobial peptides (AMP) and thereby suppress 
the TA interaction. This approach may contribute to the development of novel, 




2.2 Experimental procedure 
2.2.1 Cloning and transformation 
The genes of HicB (SP1786) and HicA (SP1787) were amplified by using 
polymerage chain reaction (PCR). The primers used in PCR are HicB-F/HicB-R 
for HicB and HicA-F/HicA-R for HicA (Table 6). Restriction enzymes used for 
cloning were Nde1 and Xho1. The PCR product of both HicB and HicA were 
double-cut by Nde1 and Xho1 and ligated to vectors which were cut by same 
enzymes. For structure determination and biological assay, HicB and HicA were 
ligated to pET21a without tag and pET28b, respectively. The pET28b N-terminal 
tag was added to HicA as an additional residual (MGSSHHHHHHSSGLVPRGSH) 
tag. For NMR experiments, residues of HicB containing DNA binding domain 
(HicB109-150) were cloned. The primer used in PCR are HicB109-150-F and HicB-R 
(Table 6). Enzyme cutting was conducted as same way and pET28b was used for 
ligation with same tag. For confirmation of residue essential in ribonuclease 
activity of HicA, His36 of HicA was mutated to Ala36 (HicA-H36A). The primers 
used in PCR are H36A-F/H36A-R (Table 6). Mutation was conducted by using 
EZchangeTM Site-Directed Mutagenesis Kit (Enzynomics, Korea) and protocol was 






























a,b F and R represent forward and reverse respectively. Enzyme sites are underlined 
above. 
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2.2.2 Protein expression and purification 
For crystallization, the cloned plasmids of HicB and HicA were co-transformed 
into E. coli Rosetta2 (DE3) pLyss competent cells. Cells were grown at 37˚C in 
Luria broth (LB) until the OD600 reached to 0.8. The protein overexpression was 
induced by the addition of 0.5 mM isopropyl 1-thio-B-D-galactopyranoside (IPTG) 
and further incubation was followed at 37 ˚C for 4h. Cultured cells were harvested 
at 11,355 x g at 4 ˚C by centrifugation and stored -80˚C. Then, harvested cells were 
suspended in buffer A (20 mM Tris-HCl, pH 7.9, and 500 mM NaCl) with 5 % 
glycerol of total volume and lysed by using ultrasonication. After centrifugation for 
1 h at 28,306 x g, supernatant containing soluble proteins was loaded to Ni2+ 
affinity open column (Bio-Rad) which was equilibrated with buffer A in advance 
and washed by buffer A containing 50 mM imidazole. Then protein bound to Ni2+ 
column was eluted by using imidazole gradient (100−700 mM) and TA complex of 
each fraction was identified by using Sodium Dodecyl Sulfate Polyacryl Amide 
Gel Electrophoresis (SDS−PAGE). Finally, the buffer containing TA complex was 
changed to buffer consisting of 20 mM Tris, pH 7.5 and 150 mM NaCl by size-
exclusion chromatography on a HiLoad 16/600 Superdex 200 prep-grade column 
(GE Healthcare) and concentrated to 10mg/ml by using Amicon Ultra centrifugal 
filer unit (Millipore). The purity of TA protein complex was verified by SDS-PAGE. 
For Ribonuclease assay, HicA and HicA-H36A were expressed and purified by 
same procedure, except that HicA was incubated 2h after IPTC induction because 
of its toxicity to E. coli. HicBA complex displaced by selenomethionine (SeMet) 
was done by same procedure, except that cells, containing HicBA complex 
displaced by SeMet were grown in M9 medium containing extra essential amino 
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acids. For NMR experiments, the N-terminal (His)6-tagged HicB109-150 protein was 
expressed in E. coli strain BL21(DE3) using M9 medium mixed with 1.0 g/l [U-13C] 
glucose and 1.0 g/l [15N] NH4Cl (Cambridge Isotopes Laboratory) as the sole 
carbon and nitrogen sources respectively. The purification steps of HicB109-150 was 
same with that of TA complex and 100 units of thrombin from human plasma 
(Sigma-Aldrich) was added to 10 mg of purified protein and further incubated 
overnight at 20 ◦C to cleave the (His)6 tag, prior to size exclusion chromatography 
in a buffer consisting of 20 mM sodium phosphate (Na Pi), pH 7, and 100 mM 
NaCl. VapC26 and VapC30 from M. tuberculosis were expressed and purified as 
reported previously (40,132). 
 
2.2.3 Crystallization, data collection and processing 
Initial crystal screening with purified HicBA complex protein was conducted 
using kits named crystal screening 1,2 and Index (Hamton Research) by mixing 1 
μl of  protein solution (at 10 mg/ml in 20 mM Tris, pH 7.5 and 150 mM Nacl) and 
1 μl of reservoir solution. Crystals of HicBA complex were grown using sitting-
drop vapor diffusion method at 4˚C. The crystallization solution for HicBA was 0.1 
M Tris, pH 8.5 and 2.0 M Ammonium sulfate. Cryoprotection for HicBA was 
achieved by adding 20% glycerol to the solution. Crystals were flash-cooled in 
liquid nitrogen before data collection. Data was collected using ADSC Quantum 
Q270r CCD detector at beamline 5C and 7A of Pohang Light Source, Republic of 
Korea. Crystals of HicBA complex belong to orthorhombic space group P21212, 
with unit cell parameters of a = 106.263 Å, b = 116.541 Å, c = 42.490 Å, α = β = γ 
= 90.00˚ for native HicBA crystal and a = 106.926 Å, b = 116.602 Å, c = 42.680 Å, 
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α = β = γ = 90.00˚ for SeMet-labeled ones. Calculated total mass of protein 
complex was 26349.7 Da including N-terminal histidine tag. All raw data were 
scaled and processed using the HKL2000 (55). The structure of HicBA complex 
from S. pneumoniae was determined at 2.80 Å resolution by single wavelength 
anomalous dispersion using SeMet. The final structure of HicBA was determined 
by molecular replacement. The data 2.30 Å of native crystal was used for structural 
analysis and SeMet data was used as model for native one. Two structures had 
almost same protein fold. Detailed statistic information is well described in Table 7. 
In SeMet structure, we determine the positions of 14 selenium sites out of total 
asymmetric unit. PHENIX (56) was first used to automatically build a total residues 
and the remaining residues were built in Coot (57) to provide the final model that 
was refined to Rwork and Rfree (58) of 20.2 and 24.0 % for SeMet one and 20.5 and 
23.6 % for native one by using REFMAC and Phenix refinement (56,59), 
respectively. Overall geometry was validated using Molprobity (60), and 98.02 % 
of the residues were in the favored region of Ramachandran plot and additional 
1.98 % were in the allowed region in the native structure. PyMOL was used to 
generate all figures (133). The electrostatic potential surfaces were calculated using 
Adaptive Poisson-Boltzmann solver (APBS) method (62). The quality of protein 




Figure 21. Purification and crystallization of HicBA from S. pneumoniae. (A) 
Column elution using engineered histidine tags. Concentration gradient is plotted at 












Table 7. Data-collection and refinement statistics for SeMet and native structures. 
(a) Data collection details. Values in parentheses are for the highest resolution shell. 
Data set SeMet Native 
X-ray source 5C beamline of 
PLS, Korea 
7A beamline of 
PLS, Korea 
X-ray wavelength (Å) 0.9795 1.0000 
Space group P21212 P21212 
Unit cell parameters   




α, β, γ (°) 90.0, 90.0, 90.0  90.0, 90.0, 90.0 
Resolution range (Å)  50.0-2.80 50.0-2.30 




Observed reflections (>1) 294526 237881 
Unique reflections 23545 24090 
<I /(I)>  50.69 (6.86)e  30.2 (5.27)e 
Completeness (%)  96.2 (88.8)e  99.7 (97.5)e 
Multiplicitya 22.9 (22.8)e 9.9 (10.1)e 
Rmerge (%)b 11.0 (66.6)e  9.2 (53.7)e 
(b) Refinement statistics 
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Data set SeMet Native 
Rworkc (%) 20.2 20.5 
Rfreed (%) 24.0 23.6 
No. of atoms / average B factor (Å2)   
Protein 3266 / 55.6 3354 / 40.4 
Water oxygen 50 / 50.14 85 / 34.06 
RMSDf from ideal geometry   
Bond distance (Å) 0.007 0.005 
Bond angle (°) 1.314 0.963 
Ramachandran statistics   
Most favoured regions (%) 96.3 98.0 
Additional allowed regions (%) 3.2 2.0 
Residues in disallowed regions 
(%) 
0.5 0.0 




PDB accession code - 5YRZ 
 
a Nobs/Nunique 
b Rmerge =  (I -  I )/   I  
c Rwork = hkl ||Fobs| - k |Fcalc||/ hkl |Fobs| 
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d Rfree was calculated same way as Rwork, but with the 5% of the reflections excluded 
from the refinement.  
e Values in parentheses indicate the highest resolution shell. 
f Root mean square deviation (RMSD) was calculated with REFMAC. 
 
2.2.4 Size exclusion chromatography coupled with multi-angle light 
scattering (SEC-MALS) 
MALS was performed to determine the oligomeric states of HicBA. Size-
exclusion chromatography was conducted on a BioSep SEC-s3000 column 
(Phenomenex) on 1260 Infinity HPLC system (Agilent Technologies). The 
scattering data were obtained in a miniDAWN-TREOS line for emission at 657.4 
nm (Wyatt Technology) and analyzed by ASTRA 6.0.1.10 software (Wyatt 
Technology). HicBA was used at 100 μM in the experiment. HicBA was run in 20 
mM Tris, pH 7.5 and 150 mM Nacl as the condition of crystallization. Experiments 
were performed at room temperature. 
 
2.2.5 Electrophoretic mobility shift assay 
To distinguish the binding affinity of HicB and HicBA to promoter DNA, 
electrophoretic mobility shift assay (EMSA) was conducted. 28-base pair DNA 
fragment from the upstream region (promoter DNA) of HicBA was added to 
proteins as a palindromic form. Palindromic sequence was selected as (forward - 
TAATAGAATAATAAGTATCACTCCTTTA, reverse - 
TAAAGGAGTGATACTTATTATTCTATTA) and the annealed dsDNA was 
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purchased from Bioneer Innovation (http://www.bioneer.co.kr/). dsDNA and 
proteins were prepared in a binding buffer consisting of 20 mM Tris pH 7.5 and 
150 mM NaCl. Varying amounts of HicB and HicBA protein were mixed with 
DNA to give a final volume of 10 μl and incubated for 20 min at 4˚C. The total 
binding solutions were loaded onto 0.8% agarose gels in 0.5 x TBE (45 mM Tris-
borate, 1 mM EDTA) buffer and the results were visualized using a Gel Doc (Bio-
Rad). 
 
2.2.6 Isothermal titration calorimetry (ITC) measurements 
ITC experiments were performed using a MicroCal 200 (GE Healthcare) at 25˚C. 
The HicB, HicBA and promoter dsDNA were prepared in a buffer consisting of 20 
mM Tris, pH 7.5 and 150 mM NaCl. dsDNA fragment from the upstream region 
(promoter DNA) of HicBA was added to proteins.  Affinity measurement was 
conducted with the protein solution (0.1 mM, 320 μl) in the cell and the promoter 
dsDNA solution (2 mM) as the injected titrant. 180 s intervals for a total of 19 
injections were used for data collection. The MicroCal Origin software was used 
for curve fitting to calculate the binding affinity (Kd), enthalpy of binding ( H) and 
entropy of binding ( S) and molar ratio. The raw data were fitted with one-site 
binding. The Gibbs free energies ( G) were calculated by using the standard 
equation G = H − T S. 
 
2.2.7 NMR study on HicB109-150 and DNA titration 
NMR spectra of HicB antitoxin were measured through Bruker AVANCE DRX 
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800 spectrometer. All of experiments were done at 298K and samples were 
prepared in a buffer of 20 mM Na Pi, pH 7, and 100 mM NaCl containing 10% 
D2O of total volume. Data was processed using NMRPipe / nmrDraw (68) and 
further analyzed by NMRviewJ (69). The data of carbonyl carbon was obtained 
through spectrum HNCO and HNCACO, and those of α/β carbon were acquired 
through the spectrum HNCACB and CBCACONH. Also, to understand the 
structural transition occurred in specific RHH domain of HicB binding to DNA, 
promoter DNA was added to HicB109-150. DNA titration was conducted four times 
in the measurement of 1H, 15N-HSQC HSQC spectrum. The concentration of HicB 
was maintained as 1 mM but DNA concentration was varied from 0 to 0.3mM 
which was 30% of protein concentration. The chemical shift perturbation (CSP) 
was calculated by nmrViewJ. The average CSP values of 15N and 1H were 
calculated from Equation 1: δN and δH account for the CSP values of the amide 
nitrogen and proton. 
                    δavg = [(0.2 × δ2N + δ2H) / 2]1/2                    (1)    
 
2.2.8 In silico HicBA-DNA docking 
In silico molecular docking for the interaction between promoter DNA and HicBA 
was performed using High Ambiguity Driven protein-protein Docking algorithm 
(HADDOCK) (134) due to difficulty of having a DNA bound crystal of HicBA. 
The coordinates for a 28-base pair promoter DNA were modeled using 3D-DART 
server (135), and coordinates for the HicBA were taken from our crystal structure. 
The in silico chimera models of HicBA hetero-octamer and HicB tetramer were 
obtained by performing a rigid-body fitting onto the model of HicBA and HicB 
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structures in Y. pestis (PDB code 4P78 and 4C26) (127). The residues of DNA 
binding domain, inferred from CSP values and two symmetrical grooves of the 
DNA were defined as ‘active residues’, to generate interface contact. Passive 
residues were defined automatically as residues around active residues. 
 
2.2.9 In vitro ribonuclease assay for the addition of peptide mimicking 
binding region 
Ribonuclease activity of HicA was confirmed using an RNase Alert kit (IDT). 
Fluorescence quenching assay was carried out following the manufacturer’s 
protocol. In this system, a fluorophore is covalently attached to one end of a 
synthetic RNA strand and quenched by a quencher group at the other end. If 
synthetic RNA containing fluorophore-quencher pair interacts with ribonuclease, 
synthetic RNA is digested and quencher gets off. Released fluorophore makes 
fluorescence at 520 nm upon excitation at 490 nm by a fluorometer. The resulting 
fluorescence (RFU) was observed on a SPECTRAmax GEMINI XS 
spectrofluorometer. Various concentration range of HicA was examined to prove 
the ribonuclease activity of HicA and reaction limits. HicA-H36A was examined in 
same method as HicA to prove indispensability of His36 in ribonuclease activity. 
Several short peptides that mimic binding region of HicA were designed and 
purchased from ANYZEN (http://www.anygen.com). Peptides were added to 
HicBA complex to release free HicA (Table 8). The peptide used for regular 
experiment was ‘ELNKYTERGIRKQAG’. Theoretically, mimicking peptides 
compete with original protein for binding and if peptides occupy binding, toxin is 
freely released and makes fluorescence in fluorescence quenching assay (67). 
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Proteins and peptide used in ribonuclease assay were prepared in 20 mM Tris, pH 
7.5 and 150 mM NaCl. The HicBA complex with peptide was incubated at 37˚C 
for 30 minutes before measuring the fluorescence. 
 
Table 8. Residues used to create mimicking peptides 
Residues (start - end) Peptide 
length 
Molecular weight 
ELNKYTERGIRKQAG (53-67) 15 1,763 
GELNKYTERGIRKQAG (52-67) 16 1,820 
ELNKYTERGIRKQAGL (53-68) 16 1,876 
GELNKYTERGIRKQAGL (52-68) 17 1,933 
 
2.2.10 In vivo cell growth assay 
For cell growth assay, the plasmids delivering HicBA, HicA and HicA-H36A 
were transformed into E. coli strain BL21(DE3). Transformed cells from single 
colonies grown on 0.1 % glucose containing-M9 medium plates were grown 
overnight and diluted to OD600 0.1. Diluted cells were further grown to OD600 
reached 0.4 and 0.5 mM IPTG was added to express proteins. Each cell was 
incubated at 37˚C for 8h after induced by IPTG and monitored at every 1h. 
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2.2.11 In vivo HicB neutralization assay 
For the neutralization assay by HicB, mutational approaches toward binding 
interface of HicBA were conducted. Six residues of HicB (Phe22, Thr33, Gln34, 
Glu47, Phe80 and Thr89) were mutated to alanine (Table 1). The resulting mutant 
proteins were designated F22A, T33A, Q34A, E47A, F80A and T89A. Mutations 
were conducted in same method as HicA-H36A and mutated HicBA complexes 
were expressed using the same procedures as native HicBA complex. The primers 
used to create these mutations are described in Table 1. pET28b-HicA along with 
pET21a-HicB or pET21a-HicB mutants were co-transformed to E. coli strain 
BL21(DE3). Transformed cells were grown in LB plate containing 0.5 mM IPTG. 
The plates were incubated 37˚C for 18h. 
 
2.2.12 Circular dichroism (CD) spectroscopy 
CD measurement of 25 μM peptides dissolved in 20 mM Tris, pH 7.5 and 150 
mM NaCl was performed in Chirascan plus spectropolarimeter (Applied 
photophysics Ltd) at 20˚C, using a 1 mm light path cell. CD scans were taken from 
260 nm to 190 nm, with 1 nm bandwidth, and a scan speed of 100 nm/min. Three 
scans were averaged, followed by subtraction of the solvent signal. 
 
2.2.13 Antimicrobial activity test 
Antimicrobial activity was evaluated by serial dilution method measuring 
Minimum Inhibitory Concentration (MIC) values. The activity of peptide was 
tested against three strains of Gram-positive (Bacillus subtilis ATCC 6633, 
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Staphylococcus aureus ATCC 6538p, Staphylococcus epidermis ATCC 12228) and 
five strains of Gram-negative (E. coli ATCC 25922, Shigella dysentariae ATCC 
9752, Salmonella typhimurium ATCC 14028, Klebsiella pneumoniae ATCC 10031, 
Pseudomonas aeruginosa ATCC 27853) bacteria. Each cell strains was grown 
overnight and incubated with various concentrations of peptide (0.4–100 μM). MIC 
was defined as the lowest peptide concentration that completely inhibits the cell 




2.3 Results  
2.3.1 Overall structure of the HicBA complex 
The asymmetric unit of the crystal structure of HicBA complex contains two 
hetero-dimeric HicBA complexes. Two HicB antitoxins and two HicA toxins form 
a hetero-tetrameric assembly (Figure 22A). However, the calculated molecular 
weight of HicBA from SEC-MALS was 105 ± 0.1 kDa, which matched the 
theoretical molecular weight of the hetero-octameric model of HicBA (105.4 kDa) 
(Figure 23A). By these result, the real oligomeric state in solution is hetero-
octamer and inconsistency with crystallographic form might be due to the unit cell 
length of unique space group. In silico model of hetero-octameric assembly of 
HicBA contains dimeric interfaces of HicB (Figure 22A and Figure 23A). 
Secondary structure analysis was conducted using 2Struc server (63).  
The S. pneumoniae HicB antitoxin contains three α-helices, three 310-helices (η) 
and four β-strands in the following order: β1 (residues 2–11), β2 (residues 21–24), 
β3 (residues 33–35), α1 (residues 38–58), η1 (residues 69–71), η2 (residues 92–94), 
β4 (residues 96–103), η3 (residues 104–106), α2 (residues 122–130), and α3 
(residues 135–146). Two antiparallel β-sheets (β4-β1-β2-β3) wrap the α1 helix and 
the α2 and α3 helices are followed by long loop after η3 helix (Figure 22B).  
 
The S. pneumoniae HicA toxin contains two α-helices and three β-strands with a 
topology of α-β-β-β-α dsRBD fold. The five secondary structure elements 
correspond to followings: α1 (residues 14–23), β1 (residues 27–28), β2 (residues 
36–40), β3 (residues 47–50), and α2 (residues 56–66). The β2, β3, and α2 of the 
HicA toxin have contacts with a curved back of the HicB antitoxin, made up of β2, 
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β3, and α1 of the HicB antitoxin. (Figure 22B). 
In comparison to the structure of Y. pestis HicBA complex (127), S. pneumoniae 
HicBA complex structure contains an additional long and flexible loop between η1 
and η2 of HicB that the Y. pestis HicBA complex does not show (Figure 24D). This 
loop covers more than 20 residues of the HicB (Figure 22B). In particular, the 
structure C-terminal region of HicB is missing in the structure of Y. pestis HicBA 
complex, which is expected to be DNA-binding domain (128) (Figure 22C). 
Structural topologies of two HicBA complex is described in Figure 25A−B. DNA 
binding domain of Type II antitoxin is important in auto-regulation of TA operon 
(52). Furthermore, DNA binding domain of the HicBA system was determined as 
RHH by NMR studies. In summary, the structure of S. pneumoniae HicBA 
complex is the first structure showing entire conformation of the HicBA TA system, 






Figure 22. Overall structures of HicBA. (A) Upper: Ribbon representation of the 
HicBA hetero-tetramer. Chains A and C of HicB are shown in purple and chains B 
and D of HicA are shown in cyan, respectively. Lower: In slico model of HicBA 
hetero-octamer. The model contains dimeric interfaces of HicBs. (B) Structure of 
the HicBA heterodimer. Start and end of long and flexible loop between η1 and η2 
of HicB are marked as red color bar. (C) The structure of Y. pestis HicBA complex. 
(B and C) Entire DNA binding region of C-terminus of HicB is only observed in 
the structure of S. pneumoniae HicBA complex in the black dotted square. The 




Figure 23. Size-exclusion chromatography (SEC)-MALS chromatograms showing 
the oligomeric states of HicBA and HicB in solution. The UV absorption at 280 nm 
(left axis, black line) and the calculated molecular weight (right axis, red line) are 
plotted as a function of the elution volume. The numbers next to the blue circled 
peak indicate the average molecular weight obtained using MALS. (A) HicBA was 
anticipated to exist as hetero-octamer and (B) HicB was anticipated to exist as a 





Figure 24. (A−B) Overall structures of HicBA and HicB. (A) Ribbon 
representation of the HicBA hetero-tetramer and 90° rotated diagram. Chains A and 
C of HicB are shown in purple and chains B and D of HicA are shown in cyan, 
respectively. (B) In slico model of HicB tetramer. The model contains two different 
dimeric interfaces in N terminus and C terminus. (C−D) Structural comparisons 
between tetrameric structures of S. pneumoniae HicB (magenta) and Y. pestis HicB 
(green). (C) C-terminal dimerization interface. (D) N-terminal dimerization 
interface. The N-terminal interface of S. pneumoniae HicB revealed a flexible loop 





Figure 25. Secondary structure topologies of Y. pestis HicBA (PDB code 4P78) 
and S. pneumoniae HicBA. (A) Secondary structure topologies of HicBs. S. 
pneumoniae HicB contains an additional long and flexible loop between η1 and η2 
of HicB that the Y. pestis HicBA complex does not show. The structure of Y. pestis 
HicB lacks C-terminal region of HicB , which is expected to be DNA-binding 
domain. (B) Secondary structure topologies of HicAs. They adopts α-β-β-β-α 
dsRBD fold. 
 
2.3.2 The structural distinctions of HicB antitoxin 
Two HicB antitoxins form a homodimer through their N-terminal domain, mainly 
by β1, α1, and β4 from each HicB monomer. However, the calculated molecular 
weight of HicB from SEC-MALS was 71.8 ± 0.8 kDa, which matched the 
theoretical molecular weight of the tetramer model of HicB (71.3 kDa) (Figure 
23B). In silico model of HicB tetramer contains additional C-terminal dimeric 
interface as well as N-terminal interface. (Figure 24B−C). The average area of the 
N-terminal dimeric interfaces is 601.9 Å. Interface area was calculated using PISA 
server (64). This binding is achieved through both hydrophobic interactions and 
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hydrogen bonding networks. Hydrophobic interactions are mediated by seven 
residues: Leu2 on β1, Ile38/Leu42/Ala43 on α1, Ile69 on η1, and Phe96/Met99 on 
β4. Met99 participates in multiple hydrophobic interactions with Ile38, Leu42, and 
Phe96 (Figure 26A). 
In addition, hydrogen bonding networks are mediated by another seven residues: 
Thr4 on β1, Ser39 on α1, Asn70 on η1, Asp93 on η2, Ser95 on the loop connecting 
η2 and β4, and Ser98/Met99 on β4. The main chain O atoms of Asp93 and Ser95 
act as an acceptor for hydrogen bonding with the Nδ2 atom of Asn70 in the η1 helix. 
The side chain Oγ atom of Ser98 accepts proton from N atom of Met99 and 
equivalent residue of proximal antitoxin. Thr4 and Ser39 also form hydrogen bond 
through their side chain atom Oγ1 and Oγ (Figure 26A). Met99 supports 
dimerization by both hydrophobic interactions and hydrogen bonding networks. 
 Interestingly, there is a considerable structural deviation in the C-terminal domain 
of two HicB antitoxins, chain A and chain C. The HicB antitoxin consists of N-
terminal fixed domain (residues 3–106), bending region (residues 107–112), and C-
terminal moving domain (residues 113–145). The rotation angle of two moving 
domains of the chan A and chain C is 151.3˚. The root mean square deviation (r.m.s. 
deviation) value of two fixed domains was 0.81, but 10.63 for whole proteins, 
because of the flexibility of moving domains. The fixed, bending and moving 
domains, rotation angle, and r.m.s deviation values were identified by the DynDom 
database (136) (Figure 26B). The r.m.s deviation of moving domains of Chain A 
and C was 0.51. These two moving domains show the difference orientation 
because of domain rearrangement. As the binding interfaces of HicB and HicA 
from chain A and C are almost same, it can be described that these moving domains 
have close relation with oligomeric state of HicBA in solution achieved by 
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dimerization of HicB. Notably, the region of expected DNA-binding domain and 
flexible moving domain are matched. This shows that flexible nature is crucial in 
their role in DNA binding (89). 
 
 
Figure 26.  Structural features of the HicB dimer. (A) Details of the homodimeric 
interface of the HicB antitoxin between chains A and C. Upper: the residues 
involved in hydrophobic interactions. Residues participating in hydrophobic 
interactions are shown as stick models. Lower: the residues involved in hydrophilic 
interactions. Hydrogen bonds are shown as black dotted lines. (B) Structural 
deviation in the C’ terminal domain of two HicB antitoxins. The fixed, bending and 
moving domains, and rotation angle are indicated. 
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2.3.3 Characterization of the interaction with promoter DNA 
To confirm the DNA-binding properties of HicB and HicBA, EMSA experiment 
was conducted. Although we could not obtain the dissociation constant by EMSA 
experiment, the binding-preference magnitudes of HicB and HicBA were identified 
based on the results. The concentration of DNA was fixed at 0.01 mM and the 
concentration of proteins was increased from 0 to 0.8 mM. As DNA binds to large 
amount of proteins gradually, the bands of DNA-protein complex shifted upward. 
(Figure 27A). EMSA shows that DNA binds to both HicB antitoxin and HicBA 
complex, exhibiting slight better affinity with HicBA than HicB. 
Isothermal titration calorimetry (ITC) experiments were used to estimate the 
binding affinity of HicB and HicBA for the promoter DNA (Figure 27B). The 
promoter DNA-binding reaction of HicB is endothermic and entropically driven, 
with thermodynamic parameters of 4.30 ± 0.39 kcal mol-1 ( H) and 33.3 cal mol-1 
deg-1 ( S), and the equilibrium dissociation constant (Kd) was measured as 8.82 ± 
1.06 μM for the binding of HicB to DNA. The binding stoichiometry (n) is 0.51 ± 
0.02 for one HicB dimer per DNA duplex. Experimental values show that HicB 
tetramer interacts with dsDNA. The promoter DNA-binding reaction of HicBA is 
endothermic and entropically driven, with thermodynamic parameters of 6.54 ± 
0.46 kcal mol-1 ( H) and 44.6 cal mol-1 deg-1 ( S), and the equilibrium dissociation 
constant (Kd) was measured as 4.18 ± 0.44 μM for the binding of HicBA to DNA. 
The binding stoichiometry (n) is 0.47 ± 0.03 for one HicBA hetero-tetramer per 
DNA duplex. Experimental values show that HicBA hetero-octamer interacts with 
dsDNA. The results show that HicBA complex has better affinity with DNA than 
HicB based on Kd values. Calorimetric trials were also performed in the absence of 
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proteins under the same experimental conditions. No change in heat was observed 





Figure 27. DNA binding properties determined from EMSA and ITC assay. (A) 
Left: EMSA experiment between HicB and DNA. Light: EMSA experiment 
between HicB and DNA. The details of the concentrations of protein and DNA in 
the lanes are indicated. The red arrows indicate gradual creation of DNA-protein 
complex at various ratios. As DNA binds to large amount of proteins gradually, the 
bands of DNA-protein complex move upward. (B) ITC assay of HicB (left) and 
HicBA (right) with the promoter DNA. The binding curve of titration indicates that 
HicB and HicBA are capable of binding to its upstream promoter DNA. Binding 
parameters are described in table (lower).  
 
2.3.4 DNA-binding domain of HicB  
In type II TA systems, the antitoxin alone or in complex with toxin typically 
interacts with its corresponding promoter DNA, repressing the transcription of the 
TA operon (52). Therefore, the DNA-binding properties of the antitoxin are 
important for the regulation of TA systems. We characterized the interactions 
between specific residues in HicB and the promoter DNA using NMR titration 
experiments. For this experiment, HicB109-150 was used because of poor spectrum 
quality of full length of HicB (Figure 28A). 
We predicted the possible DNA-binding domain of HicB and conducted 
backbone assignment of the HicB109-150 except for Pro113 and Pro121. The 
secondary structure of HicB109-150 in solution was derived from the program 
TALOS+ (78) using the assigned chemical shift values (Table 9). Predicted 
conformation of HicB109-150 includes one β-strand and two α-helices in the 
following order: β1 (residues 114–119), α1 (residues 122–130), α2 (residues 135–
145). This is highly consistent with that of the structure of HicB in the HicBA 
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complex. The oligomeric state of HicB109-150 seems likely to be dimer because of 
lacking N-terminal dimerization domain. 
We compared the HSQC spectra of HicB109-150 (1 mM) in the absence and 
presence of increasing concentrations of promoter DNA (0 to 0.3 mM). These 
comparative spectra are shown as an overlay in Figure 29A. Upon titration with 
DNA, the spectra of HicB109-150 showed peak shift. The peak shifts observed in the 
spectra indicate that the HicB109-150-DNA interaction is achieved in a fast exchange 
on the NMR time scale, which is typically observed when molecules bind with a 
low to moderate affinity. The results of the titration experiment were consistent 
with the ITC data. According to the Kd determined in the ITC experiment, the 
binding between HicB and DNA is not strong; thus, the binding mode between 
HicB109-150 and DNA is expected to show fast exchange. This result is highly 
consistent with the observed peak movements in the spectra of HicB109-150 titrated 
with DNA. 
Based on the assigned backbone 1H and 15N resonances, we monitored the 
residues showing changes in the chemical shifts upon binding to DNA. We 
calculated the combined 1H and 15N chemical shift perturbation (CSP) values of 
HicB109-150 in the presence of 0.3 mM DNA using equation 1 shown in the 
Materials and Methods section to quantify the peak shifts. These values are plotted 
as a function of HicB109-150 residues (Figure 29B). The CSP values of the residues 
belonging to the α2 helix and C-terminus were large. Residues in the N-terminus of 
the α2 helix (Phe135 and Gln137) and C-terminus (Val148 and Gln149) exhibited 
significant changes in their chemical shifts. Residues in the β1 strand showed 
relatively small CSP values than other secondary structure component because 
hydrogen bonds between β strands of HicB dimer hinder the large conformational 
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changes (137). Based on these CSP data, we characterized the DNA-binding region 
of HicB109-150 as RHH motif. The regions showing relatively large CSP values are 
mapped onto the surface representation of HicB109-150 in Figure 29C. Additionally, 
as a result of additional titration, Kd for the binding of HicBA109-150 to DNA was 
measured as 4.54 ± 1.13 μM, which is comparable to the value of Kd calculated 









Figure 28. (A) 2D 1H-15N HSQC spectrum of full-length HicB. Buffer condition 
and concentration of protein were  same as HicB109-150. (B) The superposition of 
HicA homologs. Each molecule is marked with different colors as described in 








Figure 29. NMR titration of HicB109-150 and its promoter DNA. (A) Overlay of 2D 
1H-15N HSQC spectra of 1 mM HicB109-150 with increasing ratios of added DNA. 
The peaks are colored with a gradient indicating the addition of DNA. (B) The 
chemical shift perturbation of each residue in the presence of 0.3 mM promoter 
DNA. (C) Upper: The structure of HicB109-150 in the HicBA complex. Lower: 
Surface representation of HicB109-150 mapped with CSP values. The residues are 
colored with getting darker in color indicating their CSP values. 
 
 
Table 9. Predicted secondary structures with confidence scores offered by Talos 
based on the backbone-assigned amino acid sequence of HicB109-150 
Sequence G S Q E P I K K T L 
Predicted secondary structure X L L L L E E E E E 
Confidence score 0 0 7 8 6 4 7 7 8 7 
T I P K W A D K L G R E M G L N F S Q T 
E L L H H H H H H H H H L L L L H H H H 
4 6 7 3 4 2 7 8 7 7 8 6 4 9 9 8 3 8 8 9 
L T D A I A D K K V Q A 
H H H H H H H L L L L L 
9 9 9 9 9 8 2 6 8 5 1 0 
H = helix, E = strand, L = coil, X = unassigned residues. 




2.3.5 The active site of the HicA and ribonuclease activity dependent on 
His36 
The type II toxins usually show ribonucleic activity and require essential residues 
to organize an active sites in the VapBC, RelBE, MazEF, and PezAT systems (138). 
To clarify the active site of the HicBA system, Sequence alignment were performed 
using Clustal Omega 1.2.1 (65) and visualized using ESPript 3.0 (66) (Figure 30). 
The sequence of S. pneumoniae HicA was aligned with the hypothetical protein 
from Thermus thermophiles, the HicA toxin from Y. pestis, the HicA toxin from 
Burkholderia pseudomallei, and the HicA toxin from Escherichia coli. The results 
show that highly conserved histidine residue in the β2 strand and Glycine residue 
in the loop between β1 and β2, corresponding hydrogen bonded turn. For a detailed 
comparison, the structural similarity of proteins was analyzed using DALI (70), 
except E. coli HicA, of which structure has not been reported. 
The structural homologues include (i) the hypothetical protein from T. 
thermophiles [PDB code 1WHZ (chains A) with an r.m.s. deviation of 1.5 Å, Z-
scores of 9.0 and a sequence identity of 29%], (ii) the HicA toxin from Y. pestis 
(127) [PDB code 4P78 (chains C and D) with r.m.s. deviations of 1.6-1.7 Å, Z-
scores of 7.7-8.6 and a sequence identity of 34%], and (iii) the HicA toxin from B. 
pseudomallei (131) [PDB code 4C26 (chains A) with r.m.s. deviations of 2.3 Å, Z-
scores of 5.7 and sequence identities of 28%] (Figure 31). 
 In the active site of the S. pneumoniae HicA, the key residue His36 closely 
interacts with Thr33 and Glu47 of the HicB antitoxin. The Oη1 atom of Thr33 and 
the Oε1 atom of Glu47 form hydrogen bond with the Nε2 atom and N atom of key 
residue. In addition, Oε1 atom of the Glu47 highly stabilizes the active site by 
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forming salt bridge with the Nδ1 atom of key residue. Intra-protein hydrogen bond 
is also observed between N atom of key residue and the O atom of Lys33 in the 
HicA (Figure 32). 
The S. pneumoniae HicA forms dsRBD (129) to bind to RNA substrates. The 
HicA not only binds to RNA substrates, but also cleaves the RNA substrates as 
ribonuclease toxin (130). We performed RNA activity assays for HicA using 
fluorescent RNA substrates. If the substrates are cleaved, they emit fluorescence in 
proportion to the amount of the substrate cleaved by HicA. The ribonuclease 
activity of the S. pneumoniae HicA is confirmed by the increase of RFU as a 
function of the increasing concentration of protein from 1 μM to 8 μM (Figure 
32B). At the concentration greater than 8 μM, reaction is saturated. HicA-H36A 
does not show any ribonuclease activity due to the loss of key residue. When 
compared to other toxin molecules having ribonuclease activity (VapC26 and 






Figure 30. Sequence alignment of the S. pneumoniae HicA with sequence 
homologs. Proteins are listed in order of structural homology with S. pneumoniae 
HicA. The known secondary structure elements of the proteins are shown above the 
alignment. Identical and similar residues are highlighted in red and yellow, 
respectively. Conserved residue, which is essential for ribonucleic activity is 
indicated by a red circle. 
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Figure 31. The superposition of HicA homologs. Each molecule is marked with 
different colors as described in right. The residues essential in activity are 







Figure 32. Active site structure of S. pneumoniae HicA and in vitro ribonuclease 
activity assay. (A) Active site with nearby interacting residues. Hydrogen bonds 
and salt bridge are shown as black dotted lines. (B) Upper: Fluorescence 
measurements, as a function of time, increasing addition of the HicA. Various 
concentrations of the HicA were prepared and at the concentration greater than 
8μM, reaction was saturated. The proteins having alanine mutated from histidine 
(H36A) showed negligible activity on the cleavage of the RNA molecule compared 
to HicA. (C) Ribonuclease activity comparison of S. pneumoniae HicA with other 
toxin molecules and RNase A. (B and C) 40 units of RiboLockTM (Thermo 
Scientific) RNase inhibitor were used to prevent contamination. The control 
contained 20 mM Tris, pH 7.5 and 150 mM NaCl, and 40 units of RiboLockTM 
(Thermo Scientific) RNase inhibitor. Each experiment was performed in triplicate. 
3× 10-5 units of RNase A was also used in comparison. 
- 107 -
2.3.6 Intermolecular interactions between HicB and HicA related to 
toxicity 
The HicB antitoxin blocks the enzymatic function of the HicA toxin by forming 
toxin-antitoxin protein complex. The HicB covers 1,183 Å of the HicA to 
neutralize the toxicity of HicA. Approximately, 43 % residues of whole HicA toxin 
chain D participate in this interaction and interface area occupies about 28 % of 
total suface area of HicA. 
In this interface area, hydrophobic interactions are contributed by Phe22, Met44, 
Phe80, Phe86, and Tyr90 of the HicB, and Leu50 and Tyr57 of the HicA. Aromatic 
interactions derived from Tyr57 of the HicA are major in hydrophobic interaction 
(Figure 33A). The residues involved in hydrophilic interactions in the HicB are 
Asp12/Ala19/Tyr30/Thr33/Gln34/Glu47/Thr89/Glu106/Gln111, which interact 
with Arg30/Lys33/Ser35/His36/Lys38/Glu53/Asn55/Lys56/Tyr57/Thr58/Gln65 in 
the HicA. Additional salt bridges are formed by Asp12, Glu47, Asp55, and Asp83 
of the HicB, and His36, Lys38, Lys56, and Lys64 of the HicA (Figure 33B). The 
whole hydrophilic networks are presented in schematic diagram. 
To verify the key binding residues that are essential for the interaction between 
HicB and HicA, six residues of HicB were mutated to alanine based on interaction 
analysis in Figure 33A−B. Four residues occupying hydrophilic interaction with 
multiple counterparts of HicA (Thr33, Gln34, Glu47 and Thr89) and the other two 
residues involved in hydrophobic interaction (Phe22 and Phe80) were selected. 
Among the mutated HicBA complex, HicA complexed with HicB-E47A showed 
decreased growth of E. coli, suggesting that mutation of Glu47 resulted in a loss of 
interaction between HicB and HicA. The E.coli cells containing HicA-HicB-E47A 
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Figure 33.  Heterodimeric interface of HicB and HicA, and mutations affecting 
toxicity. (A) Range of hydrophobic forces mainly contributed by Tyr57 of the HicA. 
(B) The residues involved in hydrophilic interactions. Hydrogen bonds and salt 
bridges are shown as black dotted lines. Schematic diagrams of the hydrophilic 
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interactions, indicated by red arrow from Figure 33B are presented. (C) Effects of 
mutations of interacting residues between HicB and HicA to E. coli cells growth. 
Mutated complexes were induced by IPTG to identify the toxicity to E. coli cells. 
Upper two quadrants indicate the empty vectors and native HicBA complex. 
Decreased colonies at lower quadrants indicates revived activity of mutated HicBA 
complex. 
 
2.3.7 Artificial toxin activation and cell growth inhibition by HicA 
We designed mimicking peptides as inhibitors of the interaction between HicB 
and HicA. The peptide mimics the binding interface of HicA. Theoretically, these 
mimicking peptides compete with the HicA, thus hindering the formation of the TA 
complex. If the peptide shows high affinity to the HicB, free HicA would be more 
predominant, resulting in increased RNase activity (67). The data for regular figure 
was taken from the peptide ‘ELNKYTERGIRKQAG’, based on activity 
comparison with other candidates (Figure 34A−B). Chosen peptide contains 11 
residues of the α2 helix of HicA (KYTERGIRKQA) and 11 residues of interface 
residues of HicA and HicB underlined. Peptides mimicking the helix are preferred 
because of its resistance against proteolytic degradation (139). Modeled helix 
should not be divided because of the membrane affinity and selectivity. Also, 
optimal length of helix should be modeled to prevent loss of selectivity and self-
aggregation (140). Circular dichroism spectra of peptides were collected and the 
peptide ‘ELNKYTERGIRKQAG’ showed highest degree of helicity (39.84%). The 
helical content of each peptide was quantitatively measured based on the mean 
residue ellipticity, [θ]222 (141) (Figure 34C). 
 Designed mimicking peptide includes the whole α2 helix of HicA and contains 
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seven residues (Glu53, Asn55, Lys56, Tyr57, Thr58, Lys64, Gln65) engaged in 
interactions with HicB. In the results, peptide disrupts the interaction of HicBA 
complex, up to 80 % (Figure 35A and B). RFU for peptide concentration greater 
than 16 μM did now show a remarkable difference from that of 16 μM. 
Cell growth assay demonstrated growth arrest ability of HicA and toxicity loss of 
HicA-H36A (Figure 35C). E. coli cells expressing HicA showed decreased OD600, 
after 2h from induction. Cells expressing HicA-H36A grew in same rate as control 
cells. 
Antimicrobial activity of mimicking peptide is summarized in Figure 35D. The 
peptide exhibited detectable activities against certain bacterial species. The 
strongest activities against both Gram-positive and Gram-negative bacteria were 




Figure 34. Several initial tests of peptides. The colors of lines and bars in this 
figure are corresponding to index of lower right quadrant. (A) The test of the 
RNase activity of S. pneumoniae HicBA in the presence of four peptides. 4 μM of 
peptides were added to the 4 μM of HicBA. The control contained 20 mM Tris, pH 
7.5 and 150 mM NaCl , and 40 units of RiboLockTM (Thermo Scientific) RNase 
inhibitor. Each experiment was performed in triplicate. (B) Statistical 
representation of Figure 34A. RFU obtained by the 4 μM HicAB + 4 μM 
‘ELNKYTERGIRKQAG’ was taken as 100%. Error bars represent the standard 
deviation of three replicate reactions. (C) Circular dichroism spectra of the peptides 
in a 20 mM Tris, pH 7.5 and 150 mM NaCl  at 20 ˚C. Helicities of peptides are 
expressed next to the peptide index. 
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Figure 35. Ribonuclease activity of S. pneumoniae HicBA measured using a HicA 
α2-mimicking peptide and Cell growth inhibition activity of HicA toxin and 
mimicking peptide. (A) The concentration of HicBA was fixed at 4 μM, and the 
concentration of peptide increased from 2 μM to 16 μM. The peptide inhibited the 
binding of HicB to HicA by approximately 80% at 16 μM. 40 units of RiboLockTM 
(Thermo Scientific) RNase inhibitor were used to prevent contamination. Each 
experiment was performed in triplicate.  (B) Statistical representation of Figure 
35A. RFU obtained by the 4 μM HicA was taken as 100%, and 4 μM HicBA was 
taken as 0%. The X axis indicates the concentration of added peptide. Error bars 
represent the standard deviation of three replicate reactions. (C) In vivo assay of 
HicA toxicity. Each curves of cells is represented as different colors and the data 
(OD600) is result of the average of triplicate, with standard deviations indicated by 
error bars. (D) Antimicrobial activities of mimicking peptide against various 
bacteria. Minimum inhibitory concentration was defined as the lowest peptide 
concentration (μM) that completely inhibits the cell growth after 24 h of incubation 




2.4.1 Structural uniqueness of the HicBA complex 
The HicBA structure derived from S. pneumoniae is the first structure, showing 
complete conformation of HicBA TA system. Assembling mechanism of HicBA 
complex is two dimerization strategies of HicB via its N-terminus and C-terminus. 
Interface of HicBA was studied earlier from Y. pests (127), but structural and 
functional characteristics of flexible DNA-binding domain of HicB are revealed by 
our study. Based on NMR assignments, it was confirmed that C-terminal DNA-
binding motif of HicB is RHH (73). DNA-binding domain is corresponds to 
flexible moving domain, therefore, unveiling flexible nature of HicBA is 
meaningful to give supplementary explanation to many flexible-domain-lacking TA 
complexes (138,142). In addition, because intrinsically disordered toxin-
neutralizing domain modulates the affinity between antitoxin and DNA, further 
study of relationship between protein flexibility and disorder would give crucial 
insights into reversibility of TA action including folding-upon binding (143) 
 
2.4.2 Insights into the DNA binding mechanism of the HicB 
In the structural analysis, HicB from S. pneumoniae is composed of three domains: 
fixed domain, bending domain and moving domain. Bending domain is formed 
from flexible hinge from residues 107−112. The flexibility of substrate binding 
region of protein is significantly associated with the specificity of its substrate. 
Thus conformational flexibility of binding site largely influences DNA binding 
specificity (144). Based on our study, flexible nature of HicB would play a crucial 
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role in their regulatory dynamics toward its target DNA (145). As a transcription 
regulator, flexible form of HicB is essential for the bacterial cell life and death. 
These flexible domains undergo folding transition upon binding to toxins or DNA 
to exert important regulatory function. In other words, this intrinsic flexibility of 
HicB can offer functional advantages and makes HicB to bind its target easily 
(146,147). 
 Similarly, these stabilization-upon-binding logics might be another evidence for 
better binding affinity of HicBA-DNA than HicB-DNA. HicA contributes to 
binding affinity and structural stability of HicB and DNA thermodynamically 
(91,92). This mechanical process of binding between HicBA and DNA can be 
understood by analyzing their interaction in atomic level (Figure 36A−B). In our 
model, two antiparallel β-sheets binds to the major groove of the DNA and 
electrostatically positive portion of the two α-helices anchor the DNA, facing the 
phosphates of the DNA backbone. These binding characteristics of HicBA-DNA 
interaction is mediated by stabilization-upon binding mechanism, which increases 
substrate specificity by undergoing conformation changes upon bindings of three 







Figure 36. In silico docking model of the HicBA-DNA complex, showing the 
electrostatic potential surface. Multiple solutions were clustered automatically and 
resulted in the best single cluster of docking results: The best solution showed the 
score of -128.8 ± 12.1, the smallest r.m.s. deviation (1.6 Å ± 1.0 Å), and the largest 
buried surface areas (2201.5 ± 82.8 Å
2
). (A) Electrostatically positive portion of the 
two α-helices anchor the DNA and (B) two antiparallel β-sheets binds to the major 
groove of the DNA. 
 
2.4.3 New opinions engaged in active site of HicA 
The active sites of the toxins from VapBC or RelBE family are composed of 
three to four conserved residues or more residues (44,148). These residues, 
comprising active site are counteracted by binding of their cognate antitoxins. For 
HicBA family, however, there is only one conserved histidine in reported HicA 
toxins, which is likely to contribute to toxic activity of toxin (Figure 32A). 
Mutational study also confirmed that His36 is a critical source of its activity 
(Figure 32B). Furthermore, HicA toxins are smaller than MazF, RelE and VapC in 
their size and their active site do not form any charged pocket, cluster or cavity 
(132,149,150) (Figure 37). Conserved glycine and serine near the His36 might 
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support the structural integrity of the active site. 
On the other hand, there are interesting structural discovery in mechanism of 
blocking the active site in Y. pestis (127) and S. pneumonia HicBA. In S. 
pneumonia HicBA, His36 is protruded in HicA, but inhibited by Thr33 and Glu47 
of HicB. By this interaction, these three residues construct catalytic triad (151) 
(Figure 38). Catalytic triad consists of acid, base and nucleophile. This triad is also 
found in Y. pestis HicBA. The amino acids, taking charge of acid and base are same 
for two structures as glutamate and histidine but residue acting as a nucleophile is 
different as threonine and asparagine (152). Catalytic triad is usually located in the 
active site of protease (153), but Type II toxin HicA is ribonuclease and has His36 
for its ribonucleic activity. So it is rationally suggested that the ribonucleic activity 
of HicA is inhibited by folding triad that cannot cut RNA, via binding with HicB. 
This is consistent with mutational study in HicB neutralization assay, showing 
HicA-HicB-E47A (HicBA complex having E47A mutation in HicB) re-generated 
toxicity of HicA to cells (Figure 33C). It is estimated that the role of acid is more 
important than variable nucleophiles because HicA-HicB-T33A did not show 




Figure 37. Surfaces of active sites of various toxins. (A) MazF (PDB code 4ME7) 
from B. subtilis. (B) RelE (PDB code 4FXI) from E. coli. (C) VapC26 (PDB code 
5X3T) from M. tuberculosis. (D) HicA (PDB code 5YRZ) from S. pneumoniae.  
 
Figure 38. Catalytic triads of Y. pestis HicBA (A) and S.pneumoniae HicBA (B). 
Catalytic triad consists of acid, base and nucleophile. The amino acids, taking 
charge of acid and base are same for two structures as glutamate and histidine but 
residue acting as a nucleophile is different as threonine and asparagine. 
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2.4.4 Artificial activation of the HicA by mimicking peptide as an 
antibacterial strategy 
According to shown toxicity of HicA in our study (Figure 35C), our peptide 
inhibitors can be a new antimicrobial agent by liberating HicA from HicBA 
complex. HicBA interface mimetic peptides have greatest ability to inhibit the 
interaction between toxin and antitoxin independent on the concentration of peptide, 
compared with other TA complex mimetic peptides (40,109,132). Furthermore, 
MIC could also be obtained via antimicrobial activity test, despite the relative high 
value than other highly engineered antimicrobial peptides (139,154). Because 
antimicrobial activity was more effective at higher contents of α-helix and better 
folding, (Figure 34C) we may be able to obtain a more optimized inhibitor by 
modifying the peptide by conjugation strategies and surface modulation, such as 
stapling the peptides via hydrocarbon cross linking to obtain better permeability 
and structural folding (112,115).  
The expression of HicA protein in E. coli severely reduced translation rate (155) 
and expression level of HicA in B. pseudomallei was associated with modulation of 
the formation of persister cells (131). In conclusion, based on the experimental data 
obtained in this study, peptide inducing adequate activation of HicA may be a new 





S. pneumoniae utilizes many toxin-antitoxin (TA) systems to survive. TA systems 
are strongly correlated with bacterial physiology, such as gene regulation, growth 
arrest, survival, and apoptosis. The HicBA TA family is one of the most valuable 
TA families. However, crystal structures have only been determined for the one 
incomplete HicBA TA complexes to date. The HicA toxin damages a host cell by 
inducing RNA degradation. The HicB antitoxin is an important cellular 
components for cell maintenance and viability because it neutralizes the 
detrimental activity of its cognate toxin. The HicB antitoxin acts as a repressors 
that auto-regulates the transcription of the TA operon. The HicA toxin exhibits 
ribonuclease activity toward cellular mRNAs. 
In particular, we present the crystal structure of the HicBA complex from S. 
pneumoniae at a resolution of 2.30 Å. The structure revealed the important residues 
involved in binding to the promotor DNA and in the formation of the HicBA 
complex. The HicA toxin forms double-stranded RNA binding domain (dsRBD), 
and HicB adopts a ribbon-helix-helix (RHH) DNA-binding motif. The core 
residues in HicB that bind to DNA and the structural changes in HicB resulting 
from toxin binding were clarified by nuclear magnetic resonance (NMR). The 
catalytic site of HicA is composed of histidine residue and the ribonuclease activity 
of HicA was confirmed in this study. Several peptides were designed as antibiotic 
candidates to mimic the binding interface of the HicBA complex and thereby 
suppress the TA interaction. This approach may contribute to the development of 
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